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Tiivistelmä   
Eturauhassyöpä on yksi yleisimpiä miesten syöpiä länsimaissa. Taudin rauhallinen muoto on tyypillisesti 
hitaasti enenevä, mutta sen aggressiivinen ja levinnyt muoto johtaa usein kuolemaan, minkä vuoksi uudet 
diagnoosimenetelmät ovat jatkuvan tutkimuksen alla. Prostate Specific Membrane Antigen (PSMA) on yksi 
parhaiten tutkittuja reseptoreita, joka on havaittu olevan yliekspressoitunut suurimmassa osassa eturauhas-
syöpätapauksia. PSMA-reseptoriin kohdennettuja radiolääkeaineita on kehitetty jo useita, jotka hyödyntävät 
joko kuvantamiseen sopivia radioisotooppeja (18F, 68Ga) tai hoitoon soveltuvia radioisotooppeja (177Lu).  
 
Radiolääkeaineiden ominaisuuksia voidaan muuttaa esimerkiksi fluoriglykosyloinnin avulla, joka tietyissä 
tapauksissa voi johtaa radiolääkeaineiden haluttujen ominaisuuksien parantumiseen. Tällöin molekyyli yhdis-
tetään fluoria sisältävän hiilihydraattirakenteen kanssa, joka voidaan tehdä esimerkiksi oksiimin muodostus-
reaktion avulla. Tämän pro gradu -tutkielman tarkoituksena oli kehittää kaksi uutta 18F-leimattua PSMA-
inhibiittoria hyödyntämällä oksiimin muodostusreaktiota. Prosteettisina ryhminä käytettiin kahta 18F-
leimattua hiilihydraattia: 5-[18F]fluori-5-deoksiriboosia  ([18F]9)  ja 2-[18F]fluori-2-deoksi-D-glukoosia 
([18F]12).   
 
18F-leimatun PSMA-inhibiittorin esiaste eli prekursori 3 syntetisoitiin onnistuneesti amidisidoksen muodos-
tusreaktion (saanto 56 %) ja tätä seuraavan suojaryhmien poiston avulla (saanto 29 %). Prekursorin puhdistus 
suoritettiin korkeapainenestekromatografian avulla. Prekursorin havaittiin hajoavan helposti etenkin happa-
massa ympäristössä, mutta tämä ratkaistiin kylmäkuivaamalla puhdistettu fraktio heti puhdistuksen jälkeen. 
Lisäksi prekursori 3 konjugoitiin onnistuneesti [19F]9:n (saanto 39 %) ja [19F]12:n (saanto 39 %) kanssa käyt-
tämällä oksimin muodostusta. Tätä seurasi prekursori 3:n konjugoinnit [18F]9:n ja [18F]12:n kanssa. [18F]9:n 
avulla konjugoidun molekyylin ([18F]4) leimausolosuhteet osoittautuivat huomattavasti suotuisammaksi kuin 
[18F]12:n avulla konjugoidun molekyylin ([18F]5) kohdalla. [18F]4:n oksiimin muodostusreaktio saavutettiin 
15 minuutissa huoneenlämmössä, kun reaktiota katalysoitiin 0.3 M aniliiniasetaattipuskurin avulla. Vastaa-
vasti [18F]5:n muodostusreaktio saatiin onnistumaan 30 minuutin reaktioajalla 85 ℃:n lämpötilassa. 18F]4:n 
radioleimaus onnistui 91% saannolla, kun peptidipitoisuus oli 1.5 mM. Vastaavasti [18F]5:n radioleimaus 
saavutettiin 57 % saannolla, kun peptidipitoisuus oli 9.8 mM. Lisäksi [18F]12:n tapauksessa havaittiin ylimää-
räisen sivutuotteen muodostumista, kun taas [18F]9:n tapauksessa reaktio oli spesifinen.  
 
Tuotteen [18F]4 puhdistus saavutettiin korkeapainenestekromatografian avulla, jolloin radiolääkeaineen puh-
taus oli 98%. Vastaavasti [18F]5:n puhdistuksen toimivuus osoitettiin pienellä erällä, jolloin tuotteen puhtaus 
oli 88%. Oksiimi-sidoksen hajoaminen vapaaksi [18F]12:ksi ja [18F]9:ksi oli ilmeistä ajan funktiona johtuen 
kerätyn fraktion happamuudesta. Molempien PSMA-inhibiittorien lipofiilisyys määritettiin shake flask -
uuttomenetelmällä pH:ssa 7.4. [18F]5:n logD7.4-arvoksi saatiin –2.8±0.3 ja [18F]4:n vastaavaksi arvoksi saa-
tiin -3.1±0.2. Molemmat PSMA-inhibiittorit olivat siis hyvin hydrofiilisiä. Tulevaisuudessa tutkielmassa 
käytettyjä radiosynteesimenetelmiä voitaisiin muokata korkeammille aktiivisuuksille sopivimmiksi. Lisäksi 
voitaisiin määrittää pienin tarvittava peptidikonsentraatio, minimireaktioajat molempien molekyylien oksi-
min muodostukselle sekä yhdisteiden molaariset aktiivisuudet. Ennen mahdollisia in vivo -kokeita tulisi myös 
määrittää etenkin [18F]4:n PSMA-reseptorin IC50-inhibiitiokyky, jotta voitaisiin paremmin arvioida tämän 
radiolääkkeen potentiaali uutena 18F-leimattuna PSMA-inhibiittorina. 
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Abstract 
Prostate cancer remains one of the most frequently diagnosed cancers in men. While its localized form is typi-
cally slowly advancing, the aggressive and metastasized forms are responsible for a significant amount of 
deaths in men in developed countries. Thus, more reliable methods of diagnosis are currently highly sought-
after. Prostate Specific Membrane Antigen (PSMA) remains a highly-researched receptor of choice, which has 
been found to be overexpressed in majority of prostate cancers. Several PSMA-targeting inhibitors with suita-
ble radioisotopes are already being utilized for PET imaging (18F, 68Ga) and treatment (177Lu) of prostate can-
cer, with new radiotracers possessing improved characteristics being highly sought-after.  
 
Fluoroglycosylation is a typical method of altering the properties of radiotracers, leading into more desirable 
tracer characteristics, such as increased renal excretion due to the compound’s increased hydrophilicity. This 
can be achieved with chemical reactions, such as oxime formation, where the molecule is conjugated with a 
fluorine-containing carbohydrate. The aim of this study was to develop two 18F-labeled PSMA inhibitors via 
oxime formation by utilizing two 18F-labeled carbohydrates: 5-[18F]fluoro-5-deoxyribose ([18F]9) and 2-
[18F]fluoro-2-deoxy-D-glucose ([18F]12).   
 
The precursor 3 moiety was successfully synthesized by utilizing an amide coupling reaction (yield 56%), 
followed by acid-catalyzed deprotection. The purification of precursor 3 was achieved by high-performance 
liquid chromatography (HPLC) with a yield of 29%. The precursor moiety was conjugated with [18F]9 and 
[18F]12 via oxime formation to yield compounds [19F]4 (yield 39%) and [19F]5 (yield 39%), respectively. This 
was followed by the synthesis of their respective radioisotopes, [18F]4 and [18F]5. [18F]9 exhibited more favor-
able labeling characteristics with precursor 3 compared to those of [18F]12, likely due to its readily-available 
aldehydic form, and milder reaction conditions. Conjugation of [18F]9 with precursor 3 moiety was successful-
ly achieved in 15 minutes at room temperature in the presence of 0.3 M anilinium acetate buffer, with a radio-
labeling yield up to 91% (1.5 mM peptide concentration). Comparably, conjugation with [18F]12 was achieved 
in 30 minutes at 85 ℃ in the presence of aniline, with a radiolabeling yield of 57% (9.8 mM peptide concentra-
tion). Minor by-product formation was also evident with [18F]5 while the reaction appeared more specific with 
[18F]4. 
 
Purification of [18F]4 was achieved by HPLC, yielding the radiotracer with 98% radiochemical purity. Similar-
ly, purification of [18F]5 was demonstrated with HLPC using a smaller batch, yielding the product with a radi-
ochemical purity of 88%. Minor degradation of the oxime ether bond into free [18F]9 or [18F]12 was evident as 
a function of time in an acidic environment, especially with [18F]5. The lipophilicity of the compounds was 
also demonstrated by the shake-flask method. Both compounds were found to be highly hydrophilic, with 
LogD7.4 values of –2.8±0.3 and -3.1±0.2 for [18F]5 and [18F]4, respectively. Further experiments should be 
made to optimize the radiosynthesis protocols for higher activities, and to determine the minimum peptide 
concentration and reaction time needed for the oxime ether formation. Additionally, the molar activities of the 
compounds should be determined. Also, the IC50 inhibition potency of PSMA with [18F]4 should be evaluated 
prior to any in vivo trials to better evaluate its potential as a possible PSMA inhibitor. 
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List of abbreviations  
 
ACN = Acetonitrile 
APCI = Atmospheric pressure chemical ionization 
ASAP = Atmospheric solids analysis probe 
BGO = Bismuth germinate 
BOP = Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
CT = Computed tomography 
CuAAC = Copper-catalyzed azide-alkyne cycloaddition 
DCC = N,N'-Dicyclohexylcarbodiimide 
DCY = Decay-corrected (radiochemical) yield 
DIC = N,N'-Diisopropylcarbodiimide 
DIPEA = N,N-Diisopropylethylamine 
DMF = Dimethylformamide 
DMT-Cl = Dimethoxytrityl chloride 
DMSO = Dimethyl sulfoxide 
DOTA = 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTAGA = 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-1-(1-carboxy-3-
carboxypropyl) 
DOTATOC = N-((4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacycoldodec-1-yl)acetyl-D-
phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryprophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-
hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide 
EDTA = Ethylenediaminetetraacetic acid 
EOB = End of bombardment 
ESI = Electrospray ionization 
[18F]FDG = 2-[18F]Fluoro-2-deoxy-D-glucose 
[18F]FDR = 5-[18F]Fluoro-5-deoxyribose 
[18F]DCFBC = N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine 
[18F]DCFPyL = 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-
ureido)-pentanedioic acid 
Fmoc = Fluorenylmethyloxycarbonyl 
FOLH1 = Folate hydrolase I 
FTIR = Fourier-transform infrared spectroscopy 
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Galacto-RGD = Cyclo[L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N6-(7-amino-2,6-
anhydro-7-deoxy- L-glycero-L-galacto-heptonoyl)-L-lysyl] 
GCPII = Glutamate carboxypeptidase II 
HATU =1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
 3-oxid hexafluorophosphate 
HBED-CC = N,N′-Bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic 
acid 
HBTU = 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate 
HCl = Hydrogen chloride 
HEPES = 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC = High-performance liquid chromatography 
IC50 = Half maximal inhibitory concentration 
In vitro = Research carried out in a test tube 
In vivo = Research carried out inside a living organism 
IR = Infrared 
Kryptofix222 = 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane 
LNCaP = Lymph Node Carcinoma of the Prostate 
logD7.4 = Logarithm of the distribution coefficient at physiological pH 7.4 
LOR = Line of response 
LSO = Lutetium oxyorthosilicate 
LYSO = Lutetium-yttrium oxyorthosilicate 
MA = Molar activity (previously known as specific activity) 
MRI = Magnetic resonance imaging 
MS = Mass spectrometry 
NAAG = N-acetyl aspartyl glutamate 
NaOH = Sodium hydroxide 
NFSi = N-Fluorobenzenesulfonimide 
NMR = Nuclear magnetic resonance 
NOTA = 1,4,7-Triazacyclononane-triacetic acid 
PCa = Prostate cancer 
PC-3 = Prostate cancer cell line PC-3 
PSL = Photonstimulated luminescence 
PET= Positron emission tomography 
PMPA = 2-(Phosphonomethyl)pentane-1,5-dioic acid 
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PMT = Photomultiplier tube 
PSA = Prostate-specific antigen 
PSMA = Prostate-specific membrane antigen 
PTC = Phase-transfer catalyst 
PyBOP = Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
RCY = Radiochemical yield 
SN2 = Bimolecular nucleophilic substitution 
SNAr =Nucleophilic aromatic substitution 
SPECT = Single-photon emission computed tomography  
SAM = S-adenosyl-L-methionine 
SUV = Standardized uptake value 
TBAF = Tetrabutylammonium fluoride 
TFA = Trifluoroacetic acid 
TMP = 2,4,6-Trimethylpyridine 
TLC = Thin-layer chromatography 
TOF MS = Time-of-flight mass spectrometry 
TRAP = 1,4,7-Triazacyclononane-triacetic acid 
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1 Introduction 
 
Prostate cancer (PCa) is one of the most frequently diagnosed cancers in developed coun-
tries, and among the most common causes of cancer deaths in men.1 Localized prostate 
cancer is typically curable with an early diagnosis, but the treatment options are far fewer 
with advanced disease.2 Positron emission tomography (PET) with emerging radiopharma-
ceuticals has proven to be an invaluable tool to characterize the disease in all its stages, 
especially with biochemical relapse.3 PET imaging relies on the detection of tomographic 
distribution patterns of annihilation events due to 𝛽ା decaying radionuclides, such as 18F 
and 68Ga. This enables the radiolabeling of various pharmaceuticals to monitor their distri-
bution in patients in real time.  
 
Previously, the PET imaging of prostate cancer has been limited into traditional imaging 
agents, such as [18F]FDG, [11C/18F]choline or [11C/18F]acetate.4,5 Lately, the focus on de-
veloping novel radiopharmaceuticals for PET imaging of prostate cancer has focused in 
one particularly interesting target: prostate-specific membrane antigen (PSMA).6 PSMA 
has been shown to be overexpressed in most prostate cancers, and to correlate with tumor 
aggressiveness, metastatic disease, and recurrence of the disease. This is especially valua-
ble when biochemical recurrence or progression into advanced disease is suspected.  
 
PET imaging with PSMA inhibitors has undergone vigorous research in recent years, with 
several imaging agents already being used with patients.7 The current state-of-the-art 
PSMA inhibitor in use is [68Ga]PSMA-11, which is being used worldwide in PET/CT im-
aging for the diagnosis of primary diagnosis, staging, and assessment of recurrence of 
prostate cancer.8 A similar imaging agent, [177Lu]PSMA-617 is currently in use as thera-
peutic agent for advanced disease.9 However, the inherently superior imaging quality with 
the radionuclide with a longer half-life, 18F, has lead into the emergence of several 18F-
labeled PSMA inhibitors, including [18F]DCFPyL10 and [18F]PSMA-1007,11 with the 
search for novel 18F-labeled PSMA inhibitors currently underway. 
 
The aim of this thesis is investigate the potential of two 18F-labeled carbohydrates, 5-
[18F]fluoro-5-deoxyribose ([18F]9) and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]12) as con-
jugation agents for an urea-based PSMA inhibitor. This includes the synthesis of the pre-
cursor PSMA inhibitor 3 moiety, and subsequent fluoroglycosylation via oxime formation.  
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2 Literature review 
 
2.1 Positron emission tomography 
 
Positron emission tomography (PET) is an imaging technique used to study the in vivo 
distribution and uptake of positron-emitting radionuclides in the host body.12 The tech-
nique is based on the detection of two annihilation photons with an energy of 511 keV, 
which are formed during the decay of the parent radionuclide. These annihilation photons 
are emitted at a 180° angle. As a positron travels a short distance in a medium, it will even-
tually lose its kinetic energy due to interactions with nearby electrons. The annihilation 
event happens when a positron combines with an electron, forming a short-lived and an 
instable positronium intermediate, which shortly results in the formation of annihilation 
photons. The trajectory of these photons can be detected with coincidence detectors, which 
can measure the origin of the annihilation event. However, the coincidence detectors can 
only estimate the trajectories, and further mathematical processes are needed to locate the 
exact point of origin. The spatial resolution of PET depends on the distance traveled by the 
emitted positrons, which is dependent on their emission energy. Therefore, the positron 
range can show high variability depending on the nature of the radionuclide. The range has 
a direct effect on the resolution that is attainable with PET, favoring positron emitters, such 
as 18F or 68Ga.  
 
PET is typically combined with computed tomography (CT) as it has been shown to signif-
icantly improve the information obtained when compared to the data of either CT or PET 
alone.13 This is because the obtained information is complementary, with PET emphasizing 
the part of the body with abnormal metabolism, and CT indicating local functional abnor-
malities. The combination of PET with CT also improves quantitation by providing correc-
tions for attenuation, scattering and partial-volume.14 In addition to PET/CT, combining 
PET with magnetic-resonance imaging (MRI) has also been shown to provide clinically 
significant information in a variety of diseases, including prostate cancer due to improved 
soft tissue contrast.15 The use of PET/MRI has been investigated with several radiotracers 
in clinical imaging of prostate cancer, such as [18F]fluorocholine, [18F]FDG, and 
[68Ga]PSMA-11, and it has been shown to be provide diagnostically relevant 
information.16,17 All in all, PET provides clinically invaluable information in diagnostics 
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due to its superior sensitivity and resolution compared to other imaging methods, such as 
single-photon emission computed tomography (SPECT).18  
 
2.1.1 Principle of positron emission tomography 
 
The detection of annihilation gamma rays is based on the same fundamental principle as 
with all detection methods of gamma radiation: by its tendency to interact with matter.12 
However, this can create an additional disadvantage as interaction with the host body is 
inevitable, leading into a suppressed signal due to annihilation gamma rays that never 
reach the surrounding detector system. The main interaction with the body happens by 
photoelectric interaction or Compton scattering.19 With photoelectric interaction, some 
photons will never reach the detector system, and are instead absorbed by the body. With 
Compton scattering, photons interact with the outer electrons of atoms simultaneously de-
flecting to a new direction after transferring some of the energy to them. The half-value 
layer of the 511 keV annihilation photons in water is on average 10.4 cm – a similar value 
to that of the human body.20 Thus, the probability of annihilation photons to interact before 
arriving at the detector system is significant. The loss of annihilation gamma rays is called 
the attenuation effect, and must be taken into account with PET imaging.12 
 
The simultaneous creation of gamma rays via annihilation is the major driving force be-
hind the detection system of a PET camera.19 The coincident gamma rays are emitted sim-
ultaneously in a 180° angle of each other, meaning that the measurement of coincidence 
can be done within a time window of a few nanoseconds. However, not all the detected 
gamma pairs originate from the same annihilation event. Thus, coincidence events can be 
divided into three distinct groups: true coincidence, random coincidence and scatter coin-
cidence.12 Only true coincidence events originate from the same annihilation event. Ran-
dom coincidence events are, as the name implies, originated from unrelated coincidence 
events that are detected within the limitations of the time window of the coincidence meas-
urement system. With scatter coincidence, the annihilation gamma rays originate from the 
same annihilation event, but one or two of them change direction due to Compton scatter-
ing. Thus, the coincidence event is likely assigned to the wrong line of response (LOR), 
providing additional background noise to the system.12 
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The detection system of a PET camera consists of several components: a scintillation de-
tector coupled to a photomultiplier tube (PMT), a collimator, a signal processing unit, a 
coincidence circuit, and a data acquisition system with a software for the reconstruction 
and subsequent analysis of the image.12 Modern PET cameras typically use bismuth ger-
minate21,22 (BGO), lutetium oxyorthosilicate23,24 (LSO) or lutetium-yttrium oxyorthosili-
cate25 (LYSO) as the scintillation crystal. The different scintillation crystal materials have 
their own advantages and disadvantages due to the variability in the crystal density, atomic 
number, attenuation coefficient, light output and decay time.12 While the choice of a scin-
tillation crystal can affect the intrinsic spatial resolution, it is also limited by several physi-
cal parameters, such as the detector size, positron range in tissue, and the acollinearity of 
the annihilation photons.26 Spatial resolution of 4 mm is typically achievable with clinical 
PET cameras,27 with the fundamental limit in clinical PET cameras being 2.36 mm due to 
the unavoidable physical constraints of the system.28 However, it should also be noted that 
the energy of a radionuclide also affects greatly the achievable spatial resolution: the high-
er the end-point energy, the higher the mean positron range in tissue as well.29 Thus, the 
intrinsic spatial resolution of 18F is always better than 68Ga.  
 
Typically, these scintillation detectors are made from a block of a large crystal, which is 
then further cut or channeled.12 The light of the crystal is prevented from crossing over to 
the next block with the use of light-reflective materials. The detector blocks are then con-
nected to several PMTs. Collimators are used to direct the annihilation photons to the de-
tector, and to select the desirable events. This is achieved with lead or tungsten septa, 
which can be used to selectively define the axial field-of-view (FOV) to form slices of pre-
determined size.19 The electronic circuitry of a PET camera also provides the means of an 
electronic collimation by selectively detecting only simultaneous annihilation photons dur-
ing the coincidence timing window. The collected photons are transformed into an electric 
pulse in the PMT, and processed computationally into a 2D or 3D image.12,19 
 
2.1.2 Radionuclides and radiolabeled tracers in PET imaging 
 
One typical characteristic of radionuclides in PET imaging is the short half-life.30 They are 
typically incorporated in ordinary, biochemically relevant molecules with an affinity for a 
certain receptor type in the human body. These radiolabeled molecules are also known as 
radiotracers, and are used as a diagnostic tool for monitoring changes in biology or physi-
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ology in the host body. The short half-life of these radionuclides makes the presence of a 
cyclotron, either on-site or in close proximity, a necessity. Some radionuclides, such as 
68Ga, can be produced via specifically designed radionuclide generators, making their use 
much more robust without the limitations of a cyclotron. 2-[18F]Fluoro-2-deoxy-D-glucose 
([18F]FDG) is a model example of a radiotracer that is used in modern medical diagnostics 
with PET imaging.31 It is used as a marker for glucose metabolism in the heart, lungs or 
brain, and in oncology to investigate the increase in glucose uptake by tumors. Radiotrac-
ers are used in the field of oncology, neurology and cardiology, among others.31–33 Some of 
the most traditional radionuclides, their properties, and examples of their use in PET imag-
ing are presented in table (1). 
 
Table 1. Radionuclides and examples of their use in modern PET imaging31–33 
Radio- 
nuclide 
T1/2 
Eβ, max 
(kev) 
Method of 
production 
Common 
radiotracers and examples of their use in 
clinical setting 
11C 20.39 min 960.4 14N(p,𝛼)11C 
[11C]Acetate (oncology) 
[11C]flumazenil (neurology) 
13N 9.97 min 1198.5 16O(p,𝛼)13N [13N]Ammonia (cardiology) 
15O 2.04 min 1732.0 14N(d,n)15O [15O]Water (cardiology) 
18F 109.77 min 633.5 18O(p,n)18F 
[18F]FDG (oncology) 
[18F]Fluorocholine (oncology) 
[18F]Fluorodopa (neurology) 
68Ga 67.71 min 1899.1 
68Ge/68Ga 
generator 
[68Ga]PSMA (oncology) 
[68Ga]DOTA (oncology) 
82Rb 1.26 min 3378.7 
82Sr/82Rb 
generator 
[82Rb]RbCl (cardiology) 
124I 4.18 d 2137.6 124Te(p,n)124I 
[124I]MIBG 
(cardiology & oncology) 
  
2.2 Fluorine-18 
 
Fluorine belongs to a group of elements known as halogens, which are characterized by the 
presence of two s electrons and five p electrons in the outer electron shell.34 In addition to 
fluorine, four other halogens are found in the group: chlorine, bromine, iodine, and asta-
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tine. Electronegativity of the elements within this group in the periodic table raises from 
bottom to the top, meaning fluorine possesses the highest electronegativity off all halogens 
and interestingly, of all elements as well. The electronegativity of fluorine is also responsi-
ble for its single oxidation state of -I, explaining the high stability of the F- ion. Fluorine 
also acts as an effective oxidizing agent, possessing the most oxidizing capabilities of all 
halogens. The size of a fluorine atom is similar to a hydrogen atom, which should be taken 
into account when designing fluorine-labeled molecules. Substitution with hydroxyl groups 
is also possible without any sterical changes in the molecule.35 However, the differences in 
physicochemical properties caused by the substitution should be considered. For example, 
fluorine possesses higher electronegativity, bond length, van der Walls radius and bond 
energy when compared to hydrogen atom.34 This in turn can alter the in vivo characteristics 
of a drug molecule as it undergoes hydroxylation inside the body – a typical characteristic 
of glucose metabolism. The lipophilicity of the molecule can also be altered due to the sub-
stitution of hydrogen or hydroxyl group.  
 
In principle, the reactivity of fluorine with other species can be divided into two distinct 
categories: electrophilic reactions and nucleophilic reactions.34,36 In electrophilic reactions, 
fluorine acts as an electron-deficient species with a positive charge, and it prefers to seek 
out electron-rich elements. In nucleophilic reactions, fluorine acts as an electron-rich spe-
cies, preferring to react with elements that are electron-poor. This enables the use of a wide 
variety of chemical reactions, thus providing a wide variety of possibilities in labeling re-
actions of radiopharmaceuticals. The 18F isotope also possesses invaluable characteristics 
in PET imaging due to the low positron end-point energy (633.5 keV) and short range in 
tissue. It decays by positron emission (97%) and by electron capture (3%). The long half-
life of 18F is also advantageous, enabling longer reaction times and possible transport from 
a production facility to a PET center. When fluorine is used in radiolabeling, it can be pro-
duced in high specific activities, passable labeling yields, and in large amounts if the facili-
ty is equipped with a cyclotron. 
 
2.2.1 Production of fluorine-18 
 
The production of 18F depends on whether it’s needed as a nucleophilic or electrophilic 
species for the radiolabeling reaction.37,38 In both cases, radioactive 18F is typically pro-
duced using a cyclotron with a suitable target material. In the case of nucleophilic fluorine 
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production, fluoride ion (18F-) can be produced by bombarding 18O enriched water with 
accelerated protons with the nuclear reaction 18O(p,n)18F.39  High solubility of [18F]F- 
means the addition of a carrier is unnecessary as fluoride dissolves into cyclotron target 
water immediately after irradiation, leading into high molar activities (MA), with the theo-
retical maximum being at 62900 GBq/μmol.34 Molar activities in the range of 102 
GBq/μmol can be expected with typical irradiation techniques.37,38 However, molar activi-
ties up to 5180 GBq/μmol have been achieved previously with advanced techniques.40  
 
In the case of electrophilic fluorine production, 20Ne gas is bombarded with 8-9 MeV deu-
terons with the nuclear reaction 20Ne(d,𝛼)18F.36 Alternatively, oxygen gas can be used, 
where the nuclear reaction is 18O(p,n)18F.36 Several other methods of production also exist 
in the literature, but the aforementioned methods are by far the most popular, especially 
with radiopharmaceutical applications. In both cases, stable [19F]F2 gas is added as a carri-
er to extract 18F from the cyclotron target. This leads to a significantly lower molar activi-
ty, often in the range of 600 MBq/μmol.38,41 However, alternative carrier-free production 
methods have also been developed, where [18F]F2 is produced from [18F]F- via a post-target 
generation method.42 
 
Low molar activity can be an issue if the radiolabeling strategy involves a receptor-binding 
radiotracer.43 Receptor saturation has been demonstrated to lead to a reduced PET signal 
from the receptor. Additionally, an increase in the mass of the radiotracer can cause phar-
macological effects in the host, including toxicity. This violates the general microdosing 
principle, which is often utilized with radiopharmaceuticals. By utilizing a radiotracer with 
a mass in the nanomole region, adverse effects can be avoided. With a high enough molar 
activity, even toxic compounds in subpharmacological doses can be utilized in PET imag-
ing studies.  
 
2.2.2 Radiolabeling with fluorine-18 
 
Radiolabeling strategies with 18F are often identical to the labeling methods of its stable 
isotope. However, due to the necessity of high molar activity, nucleophilic fluorination 
reactions are more common. Nucleophilic fluorination generally falls on two distinct cate-
gories of chemical reactions: aliphatic nucleophilic substitution (SN2) and aromatic nucle-
ophilic substitution (SNAr).  
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Aliphatic nucleophilic substitution reactions require a molecule with a suitable leaving 
group possessing the characteristic of a weak base.38 This includes, but is not limited to, 
functional groups in the following order of leaving ability: Cl < Br < I < tosylate = nosylate 
< triflate. The leaving group should be electronegative and stable. However, the choice of a 
leaving group also affects the likeliness of a competing elimination reaction when subject-
ed to basic conditions. Additionally, the efficacy of the substitution reaction is affect by the 
position of the leaving group, where the most efficient substitution is achieved with sec-
ondary aliphatic groups. 
 
Mechanistically, the cyclotron-produced fluoride ion attacks in the of SN2 reaction the car-
bon atom of the target molecule in an angle of 180 degrees to the leaving group.34 This in 
turn causes inversion of the configuration of the tetrahedral geometry of the aliphatic sp3 
carbon center. The 180-degree angle of the attack is necessary due to the optimal overlap 
of the nucleophilic fluoride ion’s lone electron pair and the antibonding orbital of the car-
bon-leaving group complex. Another requirement of SN2 reaction is the absence of steric 
hindrance of the sp3 carbon center. Thus, the nucleophilic attack does not occur on carbon 
centers with tertiary substrates, which are known for their steric hindrance. The reaction 
mechanism of an aliphatic nucleophilic fluorination (SN2) is shown in figure (1).  
 
Figure 1. Reaction mechanism of an aliphatic nucleophilic fluorination (SN2) reaction. 
Inversion of configuration is evident as the nucleophilic fluoride forms a new bond with 
carbon. R = suitable leaving group, such as iodide, bromide, triflate, tosylate, nosylate or 
mesylate 
 
Despite the strong nucleophilic nature of fluoride ion, it has a tendency to form hydrogen 
bonds with water molecules, greatly reducing reactivity for substitution reactions.44 Gener-
ally, cyclotron-produced 18F- is dehydrated by evaporating any water via azeotropic distil-
lation with acetonitrile, and then dissolving it in a polar aprotic organic solvent.36 The 
choice of solvent also greatly affects the reaction, which is why polar aprotic solvents, such 
as acetonitrile (ACN), dimethylformamide (DMF) or dimethylsulfoxide (DMSO) are pre-
ferred. Addition of a phase transfer catalyst (PTC), such as a potassium-complexing rea-
gent 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (kryptofix222) or tet-
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rabutylammonium cations, is also typical to enhance the solubility and nucleophilicity of 
fluoride ion. 
 
On the other hand, aromatic nucleophilic substitution reactions (SNAR) are used to add the 
nucleophilic 18F directly into the aromatic ring. SNAr reactions also require a suitable leav-
ing group.36 This includes groups such as halides, NO2 or R3N. Additionally, an electron 
withdrawing group in either ortho- or para position of the benzene ring is required for 
proper activation of the leaving group. This includes groups such as CHO, COR, COOR, 
CN or NO2. Also, high temperature and a solvent with a high boiling point (above 100 ℃) 
is needed for reactions of this type. However, isotopic exchange of 19F by 18F has also been 
achieved when using phase-transfer catalysts, such as Kryptofix222 or anhydrous tetrabu-
tylammonium fluoride (TBAF) in DMSO.45,46 The reaction mechanism of an aromatic nu-
cleophilic substitution reaction is shown in figure (2).  
 
 
Figure 2. Reaction mechanism of an aromatic nucleophilic fluorination (SN2) reaction. R1 
= suitable leaving group, such as a halide, NO2 or R3N. R2 = an electron withdrawing 
group in ortho position, such as CHO, COR, COOR, CN or NO2 
 
The cyclotron-produced [18F]F2 gas is used for radiolabeling reactions that require electro-
philic fluorination.36 Due to the nature of the gas, only one fluorine atom of the gas is 18F, 
and the other is stable 19F. This is also the reason why the molar activity of electrophilic is 
low, as the presence of a stable isotope of fluorine in the molecule leads to labeling yields 
that are inherently below 50%. Unfortunately, the addition of 19F as a carrier gas is una-
voidable as it is needed for extracting the radioactivity from the target, leading into lower 
molar activities. 
 
Several methods have been developed to solve the issue of poor molar activity of 
[18F]F2.42,47 An electrical discharge chamber can be used to convert cyclotron-produced 
[18F]F- into [18F]F2. This is achieved by converting [18F]F- into [18F]fluoromethane by nu-
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cleophilic substitution utilizing methyl iodide. [18F]Fluoromethane can then be cooled and 
purified or transferred into the aforementioned electric discharge chamber, where a con-
trolled amount of stable 19F gas is added. With this method, radiopharmaceuticals with a 
MA up to 15 GBq/µmol can be produced. The cyclotron-produced [18F]F2 gas can be used 
as is, or it can be converted into other precursors that are more easily handled in labeling 
reactions. Acetyl hypofluorite (CH3COO18F) is an example of a typical fluorination agent 
that is used for this purpose.42 Several mild electrophilic fluorination reagents have also 
been developed, including 18F-N-fluorobenzenesulfonimide (18F-NFSi) and Selectfluor.47,48 
 
While the 18F labeling reactions are typically based on nucleophilic fluorination reactions, 
sometimes electrophilic fluorination is unavoidable. This is because electrophilic fluorina-
tion enables the labeling of electron rich aromatic rings and alkenes.49,50 This, however, 
creates additional challenges with the purification of the product due to the poor regiose-
lectivity of the reactions, leading into a mixture of fluoro isomers. The production of unin-
tended isomers can be greatly diminished with organometallic precursors, such as aryltri-
methyltin.51 Electrophilic fluorination reactions are also facilitated by suitable electron 
donating groups, such as OH, OCH3, or NH2.34 The leaving groups aren’t as limited as 
with nucleophilic substitution reactions, and often only a simple hydrogen-group can suf-
fice. SnR3, SiR3 and HgR are often used in the precursor molecule as well. The reaction 
mechanism of a typical electrophilic fluorination reaction is shown in figure (3).  
 
 
Figure 3. Reaction mechanism of an electrophilic fluorination reaction. R = a suitable 
leaving group, such H, SnR3, HgR or SiR3. Regioselective electrophilic fluorination can be 
achieved with suitable electron withdrawing groups in ortho- meta- or para position 
 
Radiolabeling reactions with 18F are not only limited to the basic electrophilic or nucleo-
philic fluorination methods as described above. Transition metal mediated radiofluorina-
tion has also been investigated, where an organopalladium-based fluorination reagent has 
been utilized to form a palladium-fluorine complex.52 With complex molecules, or mole-
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cules without suitable activating groups, 18F-labeled prosthetic groups can be used 
instead.53 These labeling methods are based on either direct or indirect labeling. Indirect 
labeling methods are more typical as the reaction conditions are typically less harsh – a 
requirement for many peptides, proteins, and oligonucleotides. However, some radiolabel-
ing strategies have been developed for one-step direct labeling also. For example, Jacobson 
et al. (2011) developed a direct labeling method by replacing an aromatic nitro group of an 
arene, where a trifluoromethyl group acted as an activating group in the ortho position.53  
 
Several indirect 18F labeling methods have also been developed by introducing a prosthetic 
group to the molecule of interest.54 These prosthetic groups can be conjugated to the target 
molecule via several methods, including acylation, alkylation, amidation, imidation, oxime 
formation, or hydrazine formation. However, the use of prosthetic groups typically necessi-
tates a subsequent purification step to remove unreacted precursor and other possible by-
products.55 In recent years, a novel radiolabeling method has also gained attraction in the 
form of click chemistry by utilizing biorthogonal reactions, which are chemical reactions 
that happen rapidly in physiological conditions inside the host. This includes reactions, 
such as copper(I)-catalyzed azide-alkyne cycloaddition,56 strain-promoted alkyne-azide 
cycloaddition,57 Staudinger ligation,58 and tetrazine ligation.59  
 
2.3 Gallium-68 
 
Gallium is a naturally occurring metal that belongs to the group IIIB of the periodic table.60 
It has a filled d electron shell and three electrons in the outermost shell. As such, the most 
common oxidation state of gallium is +III. Gallium shares similarities with other metals, 
such as ferric iron (Fe3+), which is often utilized with novel radiopharmaceuticals due to 
the important role of iron in several processes in the human body. Gallium is also similar 
to other metals such as indium and yttrium, with minor differences in ionic radius and elec-
tronegativity. In nature, gallium exists in two stable isotopes: 69Ga (60.1%) and 71Ga 
(39.9%). 68Ga, however, is the primary radioisotope which is used for numerous applica-
tions in nuclear medicine. It is characterized by its short half-life of 67.71 minutes and de-
cay by positron emission (89%) and electron capture (11%).61 However, the positron emis-
sion energy of 1.9 MeV is higher compared to its common alternative, 18F. 
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Knowledge of the complexation properties of 68Ga is essential for the proper understanding 
of its chemistry. Both oxidation state and coordination number of a metal ion affect greatly 
the complexation properties of metals.61 The oxidation state is characterized by the tenden-
cy of a metal ion to form ionic bonds with ions of the opposite charge. The coordination 
number, by comparison, is characterized by the number of bonds formed between a metal 
ion and the chelating agent due to its ability to donate an electron pair. Thus, the prevalent 
oxidation state of gallium in an aqueous solution is +III, and the maximum coordination 
number is 6. This applies to pH values between 3 and 9 where Ga(OH)3 is the prevalent 
species. Gallium also has a strong affinity for hydroxide, with a tendency of forming the 
anionic complex Ga(OH)4- with high pH. 
 
2.3.1 Gallium-68 generators 
 
The production of 68Ga does not rely on the existence of a cyclotron near the labeling facil-
ity. Instead, commercial 68Ge/68Ga generators have been readily available ever since their 
invention in the 1960s.62 These generators – and the ones in current use – rely on the elu-
tion of ingrown 68Ga due to the radioactive decay of its parent nuclide, 68Ge.63 The parent 
nuclide of 68Ge/68Ga generators can be produced with a cyclotron via several nuclear reac-
tions, typically using the stable isotopes of gallium (69Ga or 71Ga). This includes reactions, 
such as 69Ga[p,2n]68Ge and 71Ga[p,4n]68Ge. Reactions that rely on the bombardment of 
deuteron or 3He/4He are also found in the literature. 
 
The early generators provided 68Ga as a negative ethylenediaminetetraacetic acid (EDTA) 
complex.63,64 However, due to the lackluster reliability in the synthesis of 68Ga radiophar-
maceuticals, these generator types were quickly replaced by more robust inorganic matri-
ces or organic resins that had a selective adsorption of 68Ge and a reliable desorption of 
68Ga when eluting with a weak hydrochloric acid solution, typically within the range of 
0.1-1.0 N. The current 68Ge/68Ga generators are still generally eluted with a weak solution 
of hydrogen chloride (HCl) as in the 1970s, but they utilize more robust 68Ge trapping ma-
trices TiO2 or SnO2. The parent nuclide 68Ge is immobilized to this inorganic matrix in the 
oxidation state of +IV. However, the elution of 68Ga is not completely free of the parent 
nuclide, leading to 68Ge breakthrough levels typically between 0.01-0.001% of the total 
activity of the eluted 68Ga. The acceptable purity and ease-of-use of the generator-eluted 
gallium has led to its widespread use in clinical applications, often preferred over 18F. 
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2.3.2 Radiolabeling with gallium-68 
 
The 68Ga that is eluted from a 68Ge/68Ga generator is found as a metal cation in the oxida-
tion state of +III.60 However, before its use for radiolabeling reactions, several metallic 
impurities must be removed, including non-radioactive Nb, Ni or Cu and Fe. The presence 
of these metallic impurities can have a significant effect on the labeling yield and molar 
activity of the radiolabeling product. Residual impurities from the column material itself 
are also often present, including Ti(IV). The acidic pH of the solution can also cause prob-
lems in the reaction, as well as the large volume of the dilute HCl solution.  
 
Three typical methods are used to reduce the amount of impurities in the 68Ga eluent: anion 
exchange chromatography, cation exchange chromatography, or fractionation.63,64 In anion 
exchange chromatography, the 68Ga eluate with a typical volume of 10 mL is transferred 
into a vial with 15 mL of 9.5 N HCl, making the final solution 5.5 N. This enables the ad-
sorption of gallium into a strong anion exchange resin as 68Ga forms a negative chloro 
complex. The 68Ga can then be washed with 5.5 N HCl, flushed with nitrogen, and eluted 
out in a controlled amount of water. Under these conditions, possible anionic 68Ge impuri-
ties are removed, but metal cations, such as Zn(II) and Fe(III) remain. In cation exchange 
chromatography, the 0.1 N HCl 68Ga eluate adsorbs quantitively into a cation exchanger 
resin, where a low volume of HCl/acetone mixture purifies it from metal cations, such as 
Ge(IV), Ti(IV), Zn(II), and Fe(III). The method is faster than the anion exchange, and 
greatly reduces the eluate volume, and thus, is often the preferred one. A relatively crude 
method is often utilized as well for pre-labeling purification in the form of fractionation. 
The first 1-2 mL of eluate typically contain up to two thirds of the total 68Ga activity. Thus, 
68Ga is eluted out of the generator into small fractions, and the fraction with the highest 
activity is used. This reduces the volume, and additionally, the amount of impurities. 
 
After the removal of impurities, the 68Ga eluate is ready for various radiolabeling reactions, 
only limited by the coordination chemistry of gallium. For this, a suitable chelating agent is 
needed, typically containing a ligand or an atom with a lone pair of electron.65 An ideal 
ligand would discriminate other metal impurities, and should be functional in a broad pH 
range and in room temperature. Several suitable chelators are often employed, such as 
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and NOTA (1,4,7-
triazacyclononane-triacetic acid). Recently, modified acyclic ligands, such as HBED-CC 
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( N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid) have 
been used as well for the conjugation of proteins. 
 
All the chelators have their own limitations. For example, chelation of DOTA with 68Ga 
often requires heating at 95 ℃ for 30 min at pH 4.6.66 This creates additional limitations 
with peptide conjugation, as high temperature and low pH often causes degradation. Radio-
labeling of NOTA can be achieved in less than 10 minutes at room temperature and pH of 
3.5.67 Despite its limitations, DOTA has numerous applications. For example its derivative, 
DOTATOC (N-((4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacycoldodec-1-yl)acetyl-D-
phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryprophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-
hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide), is used as a 
somatostatin analogue for the clinical imaging of the somatostatin receptor.68 Similarly, 
HBED-CC conjugation with 68Ga has been achieved in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer at pH 4.1 at room temperature with a 5-
minute reaction time.65 The mild labeling conditions make HBED-CC especially suitable 
for conjugation with proteins and peptides. As expected, HBED-CC has been used to suc-
cessfully conjugate various peptide based structures, including PSMA inhibitors for PET 
imaging of prostate cancer.69 Recently, other promising 68Ga chelators have also surfaced. 
Triazacyclononane-phoshinate (TRAP) chelators and their derivatives have demonstrated 
significantly improved complexation properties compared to other chelators.70,71 Structures 
of some common 68Ga chelators and their derivatives are shown in figure (4). 
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Figure 4. Some common chelators and their derivatives suitable for complexation of Ga3+ 
 
The choice of a ligand for 68Ga radiolabeling is not the only factor that must be considered 
when developing a novel radiopharmaceutical. The conjugation chemistry of the ligand to 
the precursor that binds to the studied receptor must be considered as well.72 The precursor 
moieties are often modified using carefully controlled pharmacokinetic modifiers. These 
include hydrocarbon chains, polyethylene glycol, carbohydrate and polypeptide chains – 
all of which modulate the pharmacokinetics, biodistribution and stability of the radiophar-
maceutical. The term linker or spacer is often used for these moieties. 
  
24 
 
2.4 Prostate-specific membrane antigen  
 
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein 
that is expressed in human prostate epithelium, salivary and lacrimal glands, small intes-
tine, and kidneys.6 PSMA overexpression has been observed in up to 90% of all prostate 
cancers, and in levels up to 1000 times higher than in healthy prostate epithelium and other 
cell types.73,74 PSMA overexpression has also been implicated in several other types of 
cancer, including renal cell carcinoma,75 and breast cancer,76 but so far, prostate cancer 
remains the main area of interest for PSMA based PET imaging. Overexpression of PSMA 
is not only present in most prostate cancers, but also correlated with the tumor stage and 
clinical outcome.77 PSMA overexpression is independent of androgen receptor, and thera-
py targeting it, making it an extremely valuable target for the diagnosis of advanced pros-
tate cancer. In fact, small-scale clinical trials with [68Ga]PSMA-11 for PET/CT have 
demonstrated a change in the therapeutic approach of the patient in up to 53.7% of cases.77 
 
PSMA has a molecular weight of 100 kDa, and it consists of 750 amino acids, which are 
divided into three different regions: an extracellular region, a cell membrane component, 
and a cytoplasmic component.78,79 In addition to its role in prostate carcinogenesis, PSMA 
acts as enzyme in the central nervous system, where it is called N-acetyl-L-aspartyl-L-
glutamate peptidase (NAALADase) due to its role in the metabolism of the neurotransmit-
ter N-acetyl aspartyl glutamate (NAAG). PSMA also takes part in folate absorption in the 
small intestine, where it cleaves 𝛾-linked glutamates from poly-g-glutamated folate, and is 
called folate hydrolase I (FOLH1). The term Glutamate carboxypeptidase II (GCPII) is 
also often used to address PSMA. 
 
The extracellular portion of PSMA contains a tunnel with a length of approximately 20 
Å.80 This tunnel acts as the active site of the PSMA enzyme, and is called the N-acetyl 
aspartyl glutamate (NAAG) binding pocket. The central nervous system produced NAAG 
binds to the hydrophobic pocket of PSMA, which is then followed by hydrolysis where 
NAAG is cleaved into glutamate and N-acetyl aspartate. This binding pocket is a binding 
site for all current PSMA inhibitors. Structurally, this binding pocket acts as a pharmaco-
phore, and consists of three major units: three carboxylate groups, a carbonyl oxygen con-
nected to a zinc complexation structure, and aromatic residues. When a ligand complex is 
bound to the PSMA, it is internalized to the intracellular portion of the cell via clathrin-
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coated pits by utilizing endocytosis. A simplified structure of PSMA on the surface of 
prostate epithelium is shown in figure (5). 
 
 
Figure 5. Simplified structure of PSMA. (1) Domain with unknown function. It also con-
tains a helical dimerization domain. (2) Catalytic domain with binding sites for PSMA in-
hibitors. Also contains a binding site for some antibodies. (3 & 4) Two proline and gly-
cine-rich regions with unknown function. (5) Hydrophobic transmembrane region. (6) 
Short intracellular domain with a binding site for some antibodies. Figure adapted from 
Maurer et al. (2016)81 
 
When looking at the macromolecular protein part of PSMA, there’s a definite macromo-
lecular protein structure, which can be targeted by specific PSMA-binding antibodies and 
aptamers.82–84 The enzymatic activity of PSMA also enables the use of small, anti-PSMA 
inhibitors, which are characterized by their low molecular weight. However, most of the 
antibodies and aptamers have failed to gain attraction in the clinical setting, and have 
largely been replaced by urea-based PSMA inhibitors.  
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2.4.1 Principle of PSMA inhibitors 
 
The first synthesized urea-based PSMA inhibitor was structurally similar to the current 
inhibitors in clinical PET imaging.85–87 The first inhibitors contained a glutamic acid, 
which was linked to a urea group and to another amino acid. This Lys-urea-glu-based 
structure is also known as the PSMA binding region. In principle, the active site of extra-
cellular PSMA contains a binuclear Zn2+ domain with S1 and S1’ binding subpockets, 
where the PSMA binding region interacts with the urea and carboxylate groups in its struc-
ture. 
 
The PSMA binding region is typically connected to a spacer before conjugation to a radio-
labeled domain.88,89 A spacer (or linker) is often essential for the proper binding of the in-
hibitor to the enzymatic binding site due to the relatively short length of the hydrophobic 
pocket.90 Additionally, it greatly influences the pharmacokinetic properties of the inhibitors 
by adjusting properties, such as lipophilicity and molecular weight of the molecule.88,89 
The nature of the spacer domain varies greatly, but structures such as naphthyl groups have 
shown to have a significant impact on the tumor-targeting properties of the molecule, in-
cluding pharmacokinetics and imaging contrast.89 The spacer can potentially interact via 
lipophilic tendency with the S1-accessory hydrophobic pocket, potentially explaining the 
improved pharmacokinetic properties of PSMA inhibitors with naphtyl-group containing 
spacers.  
 
The structure of a PSMA inhibitor varies greatly on the nature of the radionuclide being 
utilized. Thus, PSMA inhibitors can divided into two distinct groups: metal-based PSMA 
radioligands, which utilize a chelator in the structure (i.e. 99mTc,68Ga, 177Lu), or non-metal-
based PSMA radioligands (i.e. 18F).91,92 Many different chelators have been used in the 
literature, ranging from all-around chelators DOTA or its derivative DOTAGA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid-1-(1-carboxy-3-carboxypropyl)), to more 
specifically made chelators for PSMA, such as HBED-CC. HBED-CC is typically used 
with metal-based PSMA inhibitors due to its amine-phenol backbone, enabling complexa-
tion with +III metal ions. Due to the stability of 68Ga in the +III oxidation state, HBED-CC 
forms a thermodynamically stable complex even at low temperatures. In fact, 
[68Ga]HBED-CC-PSMA (PSMA-11) has gained enough attraction to warrant its use in 
clinical setting.8 The chelating moiety is, however, unnecessary when positron-emitters, 
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such as 18F are used. In fact, numerous radiolabeled compounds can be conjugated to the 
PSMA-binding domain when a suitable linker molecule is present, only limited by the 
chemistry of 18F itself. 
 
2.4.2 PSMA inhibitors with chelators 
 
All in all, three chelator-based PSMA inhibitors have shown significant potential in both 
diagnosis (PSMA-11) and in therapy (PSMA-617 & PSMA-I&T) of prostate cancer pa-
tients.93–95 These PSMA inhibitors all have two things in common: the chelating moiety in 
their structure that can bind radiometals, such as 68Ga or 177Lu, and the same glu-urea-lys 
pharmacophore structure that is responsible for binding to PSMA on the surface of prostate 
epithelium. The structures of these PSMA inhibitors are shown in figure (6).  
 
 
Figure 6. PSMA inhibitors with chelating properties that have undergone clinical evalua-
tion in patients with prostate cancer 
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Since the initial clinical breakthrough of PSMA-11 in 2011, the radiotracer has spread 
worldwide.7 It is classified as a urea-based PSMA inhibitor with a low molecular weight. 
The PSMA binding domain contains the pharmacophore glu-urea-lys, which is then conju-
gated to the complexing agent HBED-CC via a linker molecule Ahx. The complexing 
agent HBED-CC has proven superior to standard radiogallium complexing agent DOTA 
due to the efficient Ga3+ complexing characteristic and the increasingly lipophilic nature of 
the chelator.69  
 
PSMA-11 has gone through extensive preclinical and clinical evaluation in the past ever 
since its initial investigation by Eder et al (2012).69 The group synthesized PSMA-11 with 
a radiochemical yield (RCY) of 35% after high-performance liquid chromatography 
(HPLC) purification and a molar activity of 1000 GBq/µmol. Enzyme-based and cell-
based inhibition assays demonstrated significant values for PSMA receptor affinity with a 
IC50 (half-maximal inhibitory concentration) value of 7.5 nM, and a Ki value of 12.0 nM. 
Additionally, the compound demonstrated negligible uptake in PSMA-negative (Prostate 
cancer cell line PC-3) PC-3 cells and Lymph Node Carcinoma of the Prostate (LNCaP) 
cells, which were blocked with 2-(Phosphonomethyl)pentane-1,5-dioic acid (PMPA).  
High specific internalization and cell surface accumulation was demonstrated as well. Sub-
sequent biodistribution studies also demonstrated low liver activity (0.87% ID/g) one hour 
after injection, but comparably high kidney (139.4% ID/g), spleen (17.90% ID/g), and lung 
uptakes (2.49% ID/g). Tumor uptakes of 7.70% ID/g (LNCaP) and 1.30% ID/g (PC-3) 
were also achieved.69 Due to the promising in vivo results of the molecule, it was initially 
tested with 37 patients with prostate cancer.93 The biodistribution characteristics of this 
experiment were promising, with 83.8% of the patients showing at least one possible can-
cerous lesion, and a detection rate of 60-100% depending on the prostate-specific antigen 
(PSA) value of the patient. Corresponding to the cell experiments, the tracer demonstrated 
highest radiotracer uptake in kidneys and salivary glands. The radiotracer has been exten-
sively investigated in clinical setting, and has been adapted in various PET imaging centers 
around the world followed by the impressive results in patients.96 The radiolabeling proce-
dure of PSMA-11 has also been improved and simplified, with even a rapid single vial kit 
developed for patients in recent years.97  
 
Another interesting alternative for PSMA inhibitors is the possibility of using them as also 
for therapy. For therapeutic approach, common radioisotopes, such as 68Ga and 18F are not 
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suitable due to the nature of their radioactive decay. For radiotherapy to work, the isotopes 
must emit radiation suitable for localized irradiation of the tumor site. Of all the radioiso-
topes intended for a therapeutic approach, 177Lu has shown the most promise.88 177Lu emits 
𝛽ି particles with a mean penetration range of 670 µm in soft tissues, meaning therapy ap-
plications can be localized effectively while simultaneously avoiding unnecessary damage 
to the surrounding healthy tissue.98  Interestingly, 111In has also shown promise for radi-
oguided surgeries.99 However, these radioisotopes are unusable with the chelator of 
PSMA-11 (HBED-CC) due to the nature of the chelator. Thus, two well-investigated radio-
tracers for therapeutic use have emerged in recent years: PSMA-617 and PSMA I&T.98,100 
Both radiotracers utilize a DOTA conjugate as the chelator.  
 
PSMA-617 contains the same glu-urea scaffold as PSMA-11, but the linker region contains 
an additional hydrophobic region (naphthyl-group).88 Additionally, DOTA is used as a 
chelator instead of HBED-CC. 177Lu-PSMA-617 was synthesized with a radiochemical 
yield of 99% and molar activity of 4-40 GBq/µmol. Subsequent investigations for PSMA-
617 demonstrated high stability after 1 h in both PBS and in serum. The PSMA inhibition 
assay demonstrated a nanomolar affinity on LNCaP cells with a Ki value of 2.34 nM. Bio-
distribution studies also demonstrated a high specific uptake in LNCaP tumors (8.47% 
ID/g) and a high tumor-to-background ratio (7.8) 1 hour after injection and increasing up 
to 1058 after 24 hours. Rapid kidney clearance was also shown. Due to the promising re-
sults of the compound, it has been adapted into clinical use as a therapeutic approach for 
patients with metastatic prostate cancer with promising results.9,94,101 
 
The second promising chelator-based PSMA inhibitor for therapeutic purpose was devel-
oped by Weineisen et al. (2014).100 PSMA-I&T (imaging & therapy) utilizes a DOTA 
based chelator DOTAGA, which is capable of chelating both 68Ga and 177Lu/90Y. This 
multi-purpose PSMA inhibitor was synthesized with a molar activity of 250-300 
GBq/µmol (68Ga) and 38 GBq/µmol (177Lu). The compound demonstrated high hydro-
philicity, with a logP value of -3.6 and -3.9 for 68Ga and 177Lu, respectively. PSMA bind-
ing affinity was demonstrated with LNCaP cells, and IC50 values of 15.9 nM and 13.1 nM 
were obtained for the gallium and lutetium labeled compound, respectively. In addition, 
high internalization was demonstrated. The promising results of the radiotracer led into 
subsequent trials in mice,102 followed by patients with metastatic prostate cancer.95 
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2.4.3 PSMA inhibitors radiolabeled with fluorine-18  
 
The basic structure of PSMA inhibitors utilizing 18F is the same as with 68Ga: they both 
contain the same glu-urea-lys pharmacophore. Currently, three 18F-labeled PSMA inhibi-
tors have undergone clinical trials with patients: DCFBC, DCFPyl and PSMA-1007.8,11,103 
The structures of these compounds are shown in figure (7). 
 
 
Figure 7. Structures of three promising 18F-labeled PSMA inhibitors undergoing clinical 
trials 
 
The first 18F-based PSMA inhibitor DCFBC (N[N[(S)-1,3-dicarboxypropyl]carbamoyl]-4-
[18F]fluorobenzyl-L-cystaine), was successfully synthesized and subsequently underwent 
in vivo evaluation in 2008.104 [18F]DCFBC was synthesized with a RCY of 16% and a MA 
of 52 GBq/μmol. PSMA inhibition was demonstrated with a NAAG peptidase inhibition 
assay, where the IC50 value was calculated at 13.9 nM. Tumor uptake of 8.16±2.55%ID/g 
was observed at 60 minutes after injection in PSMA positive tumors (PSMA+ PC-3 PIP) 
while PSMA negative tumors (PSMA- PC-3 FLU) demonstrated minimal uptake. A de-
crease to 4.69±0.89%ID/g at 120 minutes was observed for PIP tumors. Structurally, the 
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compound contained the same glutamic acid and urea moieties, but instead of lysine, it was 
conjugated to a 18F-labeled benzyl mercaptan moiety via a sulphur-group. Thus, the linker 
group is significantly shorter than in many other PSMA inhibitors. Furthermore, clinical 
trials established a high blood-pool radioactivity for the compound, possibly due to its ten-
dency to bind to plasma proteins.103 
 
A second-generation PSMA inhibitor was quickly developed to improve the characteristics 
of the first-generation DCFBC.105 Structurally, [18F]DCFPyL (2-3-(1-carboxy-5-[(6-
[18F]fluoropyridine-3-carbonyl)amino]-pentyl)-ureido)-pentanedionic acid) contains the 
same glu-urea-lys pharmacophore as in most modern PSMA inhibitors. The lysine part of 
the compound is further conjugated to a 18F-labeled nicotinic acid moiety. In 2011, the 
compound was produced with a decay-corrected RCY of 36-53% and a molar activity of 
12.6-17.8 GBq/μmol. Subsequent in vivo evaluation demonstrated a Ki value of 1.1±0.1 
nM for the inhibition of PSMA – a value over five times higher than that of DCFBC when 
converted from IC50 to Ki. Biodistribution studies showed a tumor uptake of 44.2 
±9.7%ID/g at 60 minutes and slow decrease to 39.4±5.4%ID/g at 120 minutes, while the 
PSMA negative tumors had minimal uptake. 
 
Recently, [18F]DCFPyL has undergone various clinical trials for the demonstration of its 
efficiency in the clinical PET imaging of prostate cancer.8,10,106,107 In 2015, its biodistribu-
tion was evaluated with nine prostate cancer patients, where standardized uptake (SUVmax) 
values up to >100 were observed, along with tumor-to-blood-ratios of up to >50.10 Thus, 
the study concluded that the biodistribution characteristics were safe, and the accumulation 
of the compound in both primary and metastatic prostate tumors was notable, along with 
similar patient radiation doses to other PET imaging agents. Subsequent clinical trials have 
further elucidated the significance of this compound. [18F]DCFPyL was compared to the 
current state-of-art PSMA PET imaging agent [68Ga]PSMA-11 in patients with relapsed 
prostate cancer.8 [18F]DCFPyL provided comparable detection rates and, in some cases, 
improved rates, along with higher tumor-to-background ratios. In 2016, [18F]DCFPyL pro-
vided strong preliminary evidence for the successful detection of metastatic prostate cancer 
over conventional methods, such as CT and bone scan.106 PET/CT imaging with this com-
pound was further optimized in 2017, when images acquired at 60 and 120 minutes were 
compared in regards to the detection rate of prostate cancer and signal-to-noise ratio.107  
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Another 18F-labeled PSMA inhibitor has also gained attraction as of late. PSMA-1007 was 
developed based on the structure of the theranostic ligand PSMA-617.11 Structurally, the 
compound has the same glu-urea-lys pharmacophore as many of the compounds before, 
but additionally, it has a naphthyl-group containing structure similar in function to PSMA-
617, but without the DOTA chelator. 18F is conjugated to the nicotinic acid moiety, simi-
larly to DCFPyL. The compound underwent preclinical evaluation in 2016.108 The in vitro 
evaluation provided a binding affinity of 6.7±1.7 nM for PSMA, along with cell internali-
zation ratio of 67% ± 13% with PSMA-positive LNCaP. PC-3 cell line was used as the 
negative control (PSMA-negative). Biodistribution studies in LNCaP tumor bearing mice 
provided a tumor uptake of 8.0±2.4%ID/g 1 hour after injection and low tumor uptake in 
PC-3 tumor-bearing mice This was shortly followed by clinical evaluation of biodistribu-
tion, radiation dosimetry and histopathology in patients.11 PSMA-1007 was found to have 
reduced urinary clearance and similar effective doses to that of other PSMA-targeting PET 
radionuclides.  
 
Recently several other 18F-labeled PSMA inhibitors have also surfaced in the literature. 
Kelly et al. (2017) synthesized and performed pre-clinical evaluation of six 18F-labeled 
triazolylphenyl urea compounds using a Cu(I)-catalyzed click reaction of alkyne and 
[18F]fluoroethylazide.109 Decay-corrected RCY of 20-40% was obtained with a molar ac-
tivity up to 391 GBq/μmol. IC50 values of 3-36 nM were obtained for PSMA inhibition. 
Tumor uptake varied from 6-14%ID/g at 2 hours after injection. Biodistribution studies for 
two compounds (RPS-040 and RPS-041) with the most promising characteristics were 
performed, yielding tumor uptakes of 10.9 ± 1.0% and 14.3 ± 2.5%ID/g, respectively. 
 
Similarly, Krapf et al (2016) presented a class of [18F]fluorophenyl)acetylenes (FPAs) that 
were synthesized with Seyferth-Gilbert homologation.110 The compound was conjugated to 
various PET tracers, including PSMA, with a RCY of 30% and a MA of 232 GBq/μmol. 
The authors reported that biological evaluation was soon to follow. Interestingly, chelators 
have also been utilized with fluorine-18 labeling of PSMA. Boschi et al (2015) synthesized 
a Al18F radiofluorinated PSMA-11 ligand where aluminum-fluoride was used to directly 
label PSMA with a chelator, in this case HBED-CC.111,112 The compound was synthesized 
with a labeling yield of 81 ± 0.5% and a decay-corrected yield (DCY) of 49 ± 1.2% at the 
end of synthesis. Serum stability testing indicated that the compound had no decomposi-
tion up to 4 hours. A KD value of 10.3 ± 2.2 nM and cell uptake of 3.53 ± 0.78% ID was 
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observed in PSMA-positive LNCaP C4-2 cell line. Further biodistribution studies showed 
that the [Al18F]PSMA-11 uptake in PSMA-positive LNCaP implanted mice was 
18.4 ± 3.3%ID/g. 
 
2.5 Carbohydrates as prosthetic groups for fluorine-18 labeled PSMA inhibitors 
 
18F-labeling of a PSMA inhibitor can be done with a prosthetic group as an intermediary to 
modify the characteristics of the inhibitor into more favorable ones. Carbohydrates belong 
to a category, which can provide possibly advantageous improvements to the in vivo char-
acteristics of the radiotracers. This includes characteristics, such as enhanced biodistribu-
tion and a more specific targeting of the organ of choice,113 improved membrane penetra-
tion,114 advantages to metabolic stability and clearance,115 and better receptor-binding 
properties.116 Conjugation of a molecule with a carbohydrate is called glycosylation.  
 
One of the major successes in fluoroglycosylation of peptides includes the tracer 
[18F]Galacto-RGD, used for the PET imaging of αvβ3 receptor implicated in multiple pa-
thologies.117,118 The tracer utilizes a modified galactose, which has been functionalized to 
enable conjugation with the RGD peptide. In recent years, glycosylation has been utilized 
for a wide range of different therapeutic peptides.119 
 
2.5.1 Requirements of linker groups for glycosylation  
 
The role of a linker group for PSMA inhibitors is not only to provide improvements to the 
inhibitor’s pharmacokinetic properties, but also to deliver a scaffold that enables conjuga-
tion to the desired radiolabeled moiety. Amide coupling is a typical reaction that’s been 
utilized previously with several PSMA inhibitors,90,108,120,121 and a high number of peptide 
coupling reagents are described in the literature.122 However, the most widely used cou-
pling reagents typically belong to the categories of either carbodiimides or phosphonium 
and aminium salts. The general structure of these types of compounds are shown in figure 
(8). 
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Figure 8. The general structures of carbodiimides, phosphonium salts and aminium salts 
used for peptide coupling chemistry 
 
Carbodiimides were first introduced by Sheehan & Hess (1955).123 Two typical com-
pounds belonging to this category are N,N'-dicyclohexylcarbodiimide (DCC) and N,N'-
diisopropylcarbodiimide (DIC). DCC is typically utilized in solid-phase peptide synthesis 
(SPSS) due to its inexpensive nature and high-yielding coupling reactions.124 DIC is main-
ly used with fluorenylmethyloxycarbonyl (Fmoc) conjugation strategies.125 Similarly, 
(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) is a 
typical coupling reagents belonging to the phosphonium salt category. BOP and its analogs 
have been extensively researched due to its ease-of-use and rapid coupling. However, BOP 
has been largely replaced by its less carcinogenic substitute, (Benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP).126 Structurally these 
compounds are similar to aminium salts. (1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU) and (2-(1H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate) (HBTU) are typical examples of 
coupling reagents belonging to the aminium salt category.127,128 The structures of these 
coupling reagents are shown in figure (9).  
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Figure 9. Structures of common peptide coupling reagents. DCC and DIC belong to the 
carbodiimides category, BOP and PyBOP to the phosphonium salts category, and HATU 
and HBTU to the aminium salts category 
 
Albeit minor differences on how the catalysis of amide coupling is achieved, the main 
function of these coupling reagents remains the same: to catalyze the reaction to form an 
active ester between a carboxylic acid and an amine. As an example, the reaction mecha-
nism behind the activation of the carboxylic acid by HATU, and the subsequent N-
acylation of the carboxylic acid of choice is shown in figure (10). Mechanistically, the car-
boxylic acid moiety is first deprotonated by a base, and the subsequent carboxylate reacts 
with the carbon atom of electron-deficient HATU (step 1). This results in the formation of 
a HOAt anion, which reacts with the activated carboxylic acid intermediate, forming an 
activated ester (step 2). The nitrogen atom of the pyridine stabilizes the amine by forming a 
rapid hydrogen-bonded cyclic transition state (step 3). The amine of choice reacts with this 
activated ester complex to form the amide of choice (step 4).  
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Figure 10. Reaction mechanism of an amide coupling reaction with HATU as the coupling 
reagent. Two major by-products are formed in the reaction: tetramethylurea in step 2, and 
1-Hydroxy-7-azabenzotriazole in step 3 
 
Typically, at least 1 equivalent of a tertiary base is needed to generate a carboxyl uranium 
salt. Tertiary bases, such as N,N-Diisopropylethylamine (DIPEA), N-Methylmorpholine 
(NMM) or 2,4,6-Trimethylpyridine (TMP) are often utilized.129 The choice of a carboxylic 
acid depends on the purpose of the coupling reaction. For example, (Boc-aminooxy)acetic 
acid is a typical reagent that can be used to conjugated the glu-urea-lys scaffold of a PSMA 
inhibitor via peptide coupling.120 The aminooxy functionality of this linker group can be 
utilized to conjugate the molecule with a variety of compounds with a suitable aldehydic or 
ketonic functional groups. Carbohydrates are common examples of compounds with alde-
hyde groups belonging to this category.  
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2.5.2 Fluoroglycosylation of peptides via oxime formation 
 
Glycosylation can be achieved via oxime ether formation between the aminooxy-
functionalized peptide and an aldehyde or ketone. The nitrogen of the aminooxy group is 
added to the carbonyl carbon of the aldehyde or ketone, which is followed by proton trans-
fer. An elimination reaction of hydroxide occurs when the lone electron pair of the nitro-
gen replaces the hydroxide. In the final step, deprotonation of the nitrogen occurs by a base 
to yield an oxime. The reaction mechanism of oxime ether formation is shown in figure 
(11) for an aldehyde, but is similarly applicable for ketones as well.  
 
 
Figure 11. Reaction mechanism of oxime ether formation between an aminooxy-
functionalized peptide and an aldehyde 
 
Fluorine-18 labeled carbohydrates, such as 5-[18F]fluoro-5-deoxyribose ([18F]FDR) and 2-
[18F]Fluoro-2-deoxy-D-glucose ([18F]FDG) are also interesting targets due to their relative-
ly simple and well-established radiosynthesis protocols. In fact, several already established 
radiotracers have utilized fluoroglycosylation strategies using oxime formation.130–138 
These radiotracers are summarized in table (2). 
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Table 2. 18F-Fluoroglycosylated radiotracers utilizing oxime formation 
Publication Target 
Carbohydrate 
moiety 
Reference 
Wuest et al. 2008 Apoptosis FDG 130 
Namavari et al. 2009 
Hultsch et al. 2009 
Dall’Angelo et al. 2013 
Integrin 𝛼௩𝛽ଷ 
FDG 
FDG 
FDR 
131 
132 
133 
Al Jammaz et al. 2012 Folate receptor FDG 134 
Wuest et al. 2009 Neurotensin receptor FDG 135 
Li et al. 2013 
Vascular adhesion pro-
tein 1 (VAP 1) 
FDR 139 
Frau et al. 2013 
Cannabinoid receptors 
CB1/CB2 
FDG, FDR 137 
Keinänen et al. 2016 Pretargeted PET FDR 138 
 
2.5.3 Alternative fluoroglycosylation strategies 
 
Glycosylation of peptides has also been attempted with other carbohydrates.117,140 The 
most successful example has been the development of [18F]Galacto-RGD (Cyclo[L-
arginylglycyl-L-α-aspartyl-D-phenylalanyl-N6-(7-amino-2,6-anhydro-7-deoxy- L-glycero-
L-galacto-heptonoyl)-L-lysyl]), which utilizes a galactose analog as the glycosylating moi-
ety.117 The previously described method of oxime formation requires the presence of a car-
bohydrate in its aldehydic or ketonic form. This, however, is not possible with all glyco-
sylation moieties, and different strategies are warranted.  
 
One example of an alternative glycosylation strategy includes the newly established “click 
chemistry”, where chemical reactions are performed in mild, aqueous reaction conditions 
with high yields and minimal by-product formation.141 One of the most widely used click 
chemistry methods for glycosylation includes copper-catalyzed azide-alkyne cycloaddition 
(CuAAC), which has been utilized in the synthesis of a wide variety of radiotracers.140,142–
144 With CuAAC, the conversion of a carbohydrate moiety into its aldehydic or ketonic 
form is unnecessary due to the utilization of cyclic form of the compound. CuAAC-based 
click chemistry involved in 18F-fluoroglycosylation generally involves the conversion of 
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organic azides and terminal alkynes into 1,4-disubstituted 1,2,3,-triazoles. The reaction is 
catalyzed by copper(1).56 Examples of radiotracers developed by CuAAC 18F-
fluorogylcosylation strategies are shown in table (3). 
 
Table 3. An overview of some of the 18F-fluoroglycosylated radiotracers developed by 
CuAAC click chemistry 
Publication Target 
Carbohydrate 
moiety 
Reference 
Maschauer et al. 2014 Integrin 𝛼௩𝛽ଷ 
fluorinated glucose, 
galactose, maltose, and 
cellulose analogues 
140 
Pisaneschi et al. 2013 
Epidermal growth 
factor receptor EGFR 
FDG 142 
Maschauer et al. 2009 
Neurotensin receptor 
NTS-1 
FDG 143 
Banerjee et al. 2013 
Dopamine Receptor 
D4 
FDG 144 
 
2.5.4 2-[18F]Fluoro-2-deoxy-D-glucose  
 
2-[18F]Fluoro-2-deoxy-D-glucose is a well-established glucose analogue used in clinical 
PET imaging of various pathologies.145 The 2-carbon of FDG is replaced with a more elec-
tronegative fluoride atom. Due to the replacement of hydroxyl group at the 2-carbon, the 
molecule cannot be subjected to further metabolism in the cells after facilitated transport 
and phosphorylation by hexokinase, and instead, it accumulates inside the cells. As such, it 
can be used to monitor glucose uptake and cell viability. [18F]FDG exists as both cyclic 
and linear forms as shown in figure (12).  
 
Figure 12. Cyclic and linear forms of 2-[18F]fluoro-2-deoxy-D-glucose 
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At first, the production of [18F]FDG was carried out with electrophilic fluorination by us-
ing 3,4,6–tri–O–acetyl–D–glucal as the precursor.146 However, modern [18F]FDG synthesis 
is typically carried out with nucleophilic fluorination using 1,3,4,6–O–Acetyl–2–O–
trifluoro-methanesulfonyl–beta–D–mannopyranose (mannose triflate) as the precursor.147 
The method has been vigorously developed, and as a result, it has been fully automated 
and widely adapted for clinical use. 
 
A typical radiosynthesis of [18F]FDG begins with the removal of 18O water from 18F if pro-
duced by cyclotron.147 Due to the high hydration energy of fluorine, water must be re-
placed with a suitable polar aprotic solvent, such as acetonitrile to facilitate SN2 nucleo-
philic substitution. This can be achieved with simple anion exchange columns, where the 
retained 18F- is eluted with a mixture of Kryptofix222, potassium carbonate and acetonitrile. 
Kryptofix is a crown ether, forming a soluble counter-ion with potassium and subsequently 
preventing the formation of 18F-KF. Trace amounts of water can then be removed with 
azeotropic distillation using acetonitrile. Mannose triflate can then be added. The triflate 
group of the precursor acts as a leaving group, where 18F- ion attacks the carbon at 2-
position to form the fluorinated intermediate. The remaining hydroxyl groups of the inter-
mediate are protected by acetyl groups to prevent unintended fluorination of the hydroxyl 
groups. They can be readily removed with either hydrogen chloride (HCl), or by base hy-
drolysis with sodium hydroxide (NaOH). The compound is then typically trapped in a C-18 
reverse phase column, rinsed to remove impurities, and subjected to removal of protecting 
groups by adding NaOH. The product can then be eluted out with water, while leaving the 
partially hydrolyzed compound intact in the column.  
 
Final purification of [18F]FDG can be performed with a combination of anion exchange 
columns, C-18 reverse phase columns and alumina columns.147 The quality of [18F]FDG is 
typically determined by TLC and HPLC by characterizing the radiochemical and chemical 
purity of the product. A well-established TLC method utilizes acetonitrile:water (95/5 v/v) 
as mobile phase to yield Rf values of 0.45, 0.0 and 0.8-0.95 to [18F]FDG, free 18F- and 
acetylated [18F]FDG, respectively. The purified product can then be utilized as is, if formu-
lated to a suitable form for injection into a patient, or further conjugated with a compound 
of choice, such as a peptide. However, it should be noted that the [18F]FDG from a routine 
synthesis also contains a significant amount of D-glucose with a concentration typically in 
the range of 50-250 µg/mL.148 This can have a noticeable effect in the radiochemical purity 
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and yield of a [18F]FDG-conjugated peptide, as glucose competes with [18F]FDG with pep-
tide bond formation. This can be solved by subjecting [18F]FDG to HPLC purification prior 
to conjugation with the peptide.131,132  
 
Due to the high availability of [18F]FDG in PET pharmaceutical chemistry, and often fully 
automated synthesis, it can be an interesting conjugation agent for aminooxy-
functionalized PSMA ligands. It has been successfully conjugated with various peptides in 
previous studies.131,132,135 However, the reaction conditions have been reportedly harsh 
with heating at 120 ℃ for 20 minutes at pH 2.5.132 Wuest et al. (2009) reported reaction 
times of 30 minutes at 80 ℃ in a mixture of methanol and aqueous [18F]FDG with radio-
chemical yields of 63% and 80%, respectively.135 However, relatively high peptide concen-
trations of 2.5 mg/mL to 12 mg/mL were required. Similarly, Namavari et al. (2009) re-
ported the necessity of low pH (1.5-2.5) and high temperature (100 ℃) to obtain maximal 
radiochemical yields.131 At pH 4 in ammonium acetate buffer, product formation was not 
observed. 
 
Harsh conditions (low pH and high temperature) are often unsuitable for larger peptides 
and proteins due to the high likelihood of thermal degradation, making the utilization of 
the reaction challenging in some cases.131 However, high temperature is likely required in 
order to ensure satisfactory equilibrium conditions of its cyclic for linear form, as only the 
linear form contains the aldehyde functionality required for aminooxy-functionalization. A 
recent study by Khoshbakht et al. (2016) also utilized a long reaction time (30 min) at high 
temperatures (80-120 ℃) to yield the [18F]FDG-labeled peptide.149 Interestingly, they re-
ported an optimal pH for oxime bond formation at 5-5.5 with 0.2-5 mg of peptide used and 
a glucose concentration of 50-250 μg/mL. Low amount of cold glucose in the reaction mix-
ture has reportedly led into higher radiochemical purities (>95% purity with glucose levels 
<50 μg/mL) when labeling peptides with [18F]FDG.148 A high amount of non-labeled FDG 
hinders the reaction due its role as a competitive aldehyde source for conjugation, leading 
into decreased molar activity.  
 
2.5.5 5-[18F]Fluoro-5-deoxyribose 
 
5-Fluoro-5-deoxyribose (FDR) is an aldose sugar with a similar structure to that of FDG, 
including 𝛼- and 𝛽-anomers, and an open chain linear aldehyde form in addition to the 
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cyclic form.150 [18F]FDR is not currently used in clinical setting as a PET tracer, but in-
stead, its utility lies in the possibility of bioconjugation with peptides.136,138,150 However, 
recently [18F]FDR has been suggested as a novel tracer for tumor imaging with comparable 
performance to that of [18F]FDG.151 The structures of both cyclic and linear forms of 
[18F]FDR are shown in figure (13). 
 
 
Figure 13. Cyclic and linear forms of 5-[18F]fluoro-5-deoxyribose 
 
The synthesis of [18F]FDR is similar to that of [18F]FDG, with 18F- being produced by a 
cyclotron, and trapped into an anion exchange cartridge and eluted with K18F-Kryptofix 
2,2,2 complex in dry acetonitrile. The precursor requires a suitable leaving group, such as 
tosylate to enable fluorination. Methyl-2,3-O-isopropylidene-5-O-(p-toluenesulfonyl)-β, d-
ribofuranoside (p-TOS-FDR) has been utilized in the literature as a precursor with methyl 
and acetonide protecting groups.136,150 The precursor can be readily prepared from D-ribose 
with perchloric acid in the presence of 2,2,dimethoxypropane and methanol.152,153 The pro-
tecting groups can then be removed by acid hydrolysis and the compound purified with 
HPLC to produce [18F]FDR with a yield up to 80% and radiochemical purity of 98%.136 An 
alternative synthesis route for [18F]FDR has also been established in the literature. 
Dall’Angelo et al. (2013) successfully synthesized [18F]FDR in a two-step synthesis with 
fluorinase as an enzyme catalyst using S-adenosyl-L-methionine (SAM) as the precursor 
material.154 
 
Conjugation of [18F]FDR with peptides has been achieved with robust results and substan-
tially less harsh reaction conditions compared to FDG.136 Li et al. (2014) successfully in-
troduced a method where 0.3 mM of peptide was reacted with [18F]FDR in 0.3 M anilini-
um acetate buffer (pH 4.6). The reaction was carried out at room temperature in 10 minutes 
– a major improvement to the harsh reaction conditions of [18F]FDG conjugation. In the 
reaction, aniline acts as a nucleophilic catalyst in the reaction by changing the electrophile 
from protonated carbonyl to a more populated protonated aniline Schiff base. The subse-
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quent intermediate reacts to yield an oxime by transimination in acidic aqueous condi-
tions.155,156 The proposed reaction mechanism of this process is presented in figure (14). 
 
 
Figure 14. Proposed reaction mechanism of aniline-catalyzed oxime formation in acidic 
media 
 
Several factors affect the aminooxy conjugation of FDR. An increase in ligation rate from 
40-fold to 400-fold has been observed with aniline catalysis when lowering the pH from 
7.0 to 4.5.156,157 The presence of sodium acetate (100 mM) also increased the ligation mod-
erately by 1.5-fold. However, when the concentration was further increased to 1 M, the 
ligation improved 6.4-fold. It has been suggested that the presence of other carboxylate-
containing acids, such as trifluoroacetic acid (TFA) and sodium citrate might act as activat-
ing agents that promote the oxime formation.  
 
The reason for the ease of conjugation of FDR compared to FDG is likely due to the loca-
tion of electronegative fluorine at carbon-5.133 Additionally, the 5-carbon ring structure of 
FDG favors the opening to the linear aldehydic form compared to that of the 6-carbon ring 
of FDR. The location of electronegative fluorine at carbon-2 reportedly inhibits the ring 
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opening, and subsequently forces the use of harsh reaction conditions to favor the for-
mation of oxocarbenium ion for aminooxy-functionalization.  
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3 Experimental work 
 
3.1 Aim of the thesis 
 
The experimental part of this master’s thesis focused on developing two novel 18F-labeled 
PSMA inhibitors. This included the synthesis of the precursor moiety, and the subsequent 
conjugation with two well-established 18F-labeled sugar moieties: 2-Deoxy-2-[18F]fluoro-
2-D-glucose ([18F]12 or [18F]FDG) and 5-[18F]fluoro-5-deoxyribose ([18F]9 or [18F]FDR). 
The aim was to investigate the preliminary viability of these novel PSMA inhibitors for 
PET imaging of prostate cancer. However, it should be noted that experimental data on the 
[18F]FDG conjugated molecule was published by an another research group during this 
project,120 and as such, only the results of the [18F]FDR conjugated molecule shown herein 
are novel.  
 
In the experimental part of the thesis, the first goal of the synthesis was to conjugate the 
commercially available tert-butyl protected PSMA inhibitor 1 with (Boc-aminooxy)acetic 
acid (6) using a well-established amide coupling reaction to yield intermediate 2 (figure 
15). Before conjugation with the fluorine-containing carbohydrates [18/19F]9 and [18/19F]12 
to yield compounds [18/19F]4 and [18/19F]5, it was necessary to remove the tert-butyl ester 
and tert-butyl carbamate groups, which acted as protecting groups to prevent undesired 
functionalization. Removal of tert-butyl ester was also essential due to the necessity of 
unhindered carboxylic acid functional groups, which interact with the binding site of 
PSMA on the surface of prostate epithelium.  
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Figure 15. An overview of the synthesis scheme of [18/19F]4 and [18/19F]5 
 
3.2 Materials and methods 
 
3.2.1 General 
 
All chemicals, reagents and solvents used for synthesis and analysis during this project 
were analytical grade. The precursor PSMA inhibitor 2-{3-[1-tert-butyl-carboxylate-(5-
aminopentyl)]-ureido}-di-tert-butyl pentanedioate (1) was purchased from Futurechem. 
Other reagents for the organic synthesis were 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate (HATU) (Sigma-Aldrich), N,N-
Diisopropylethylamine (DIPEA) (Sigma-Aldrich), (Boc-aminooxy)acetic acid (6) (Sigma-
Aldrich), N,N-Dimethylformamide (DMF) (Sigma-Aldrich), trifluoroacetic acid (TFA) 
(Fisher scientific), dichloromethane (DCM) (Sigma-Aldrich), 2-deoxy-2-fluoro-2-D-
glucose (FDG) (Omicron) and 5-fluoro-5-deoxyribose (FDR) (kindly provided by Outi 
Keinänen, Department of Chemistry, University of Helsinki). Precursors for the radiolabel-
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ing reactions were 1,3,4,6–O–Acetyl–2–O–trifluoro-methanesulfonyl–beta–D–
mannopyranose (10) (Sigma-Aldrich) and methyl 2,3-O-isopropylidene-5-O-(p-
tolylsulfonyl)-beta-D-ribofuranoside (7) (kindly provided by Outi Keinänen, Department 
of Chemistry, University of Helsinki). Other reagents and solutions used in radiolabeling 
reactions were 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane (Kryp-
tofix222) (Sigma-Aldrich), and DNA-quality acetonitrile (Merck). Other general solvents 
and chemicals were purchased from trusted vendors.  
 
Purity of the synthesis products was characterized with several methods, including nuclear 
magnetic resonance (NMR), high-performance liquid chromatography (HPLC), thin-layer 
chromatography (TLC), and mass spectrometry (MS). 1H-NMR and 13C-NMR spectra 
were recorded on a Varian 300 MHz spectrometer. Chemical shifts in this thesis are given 
in ppm referenced to internal standards or known signals. Abbreviations were used as fol-
lows: s = singlet, bs = broad singlet, d = doublet, dd= doublet of doublet, t = triplet, m = 
multiplet. Deuterated solvents were used to obtain the NMR spectra (D2O or CDCl3).  Rap-
id analysis of reaction mixtures and fractions was performed on an Advion expression 
CMS with either positive or negative mode using atmospheric pressure chemical ionization 
(APCI). High-resolution mass spectra were recorded with Bruker Daltonics microTOF 
benchtop electrospray ionization time-of-flight mass spectrometer (TOF-ESI-MS) with 
either negative or positive mode. Purity of crude reaction mixtures was assessed by TLC 
and HPLC. TLC was carried out using HF254 silica plates. Radio-TLC was analyzed with 
digital autography using photonstimulated luminescence imaging plates (PSL) by Fujifilm, 
and scanned with FLA-5100 scanner instrument. HPLC analyses and purifications were 
performed with two different columns: Alltima C18 semi-preparative column (5 um, 250 x 
10 mm) (Grace Discovery Sciences) or Alltima C18 analytical column (5 µm, 250 x 4.6 
mm) (Grace Discovery Sciences). HPLC1 instrument (Shimadzu) was used for all anal-
yses. UV detection was performed at wavelengths 209 nm and 254 nm. Radioactivity de-
tection was performed with a well-scintillation type NaI(Tl) detector. HPLC purification of 
the radiolabeling products during synthesis was performed with a Hitachi L-7100 HPLC 
system using Phenomenex DG-4400 degasser. HPLC spectra was recorded with Amer-
sham Pharmacia Biotec Rec 112 analog recorder device.  
 
Production of [18F]fluoride- for the radiosynthesis of [18F]4 and [18F]5 was performed with 
Cyclone 10/5 D2 cyclotron by Ion Beam Applications. The 18O (≥ 98%) enriched H218O 
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was purchased from IASON GmbH. An automated synthesis unit by DM automation was 
utilized for the synthesis. The synthesis unit was connected to an argon gas line and to the 
fluorine line from the cyclotron. The argon gas flow in the system was adjustable by a nee-
dle valve outside the system. The automated synthesis unit also had two- and three-way 
valves (Bürkert Fluid Control Systems), heating and cooling interfaces for the reaction 
vessels, and radiation monitors. The valves of the automated synthesis unit were adjustable 
by a touch screen interface.  The lead-shielded cabinet also hosted a dose calibrator by 
Veenstra Instruments. 
 
Several solutions were also prepared in the laboratory using the following protocols: 
 
1.2 M Anilinium acetate buffer (pH 4.6) 
Aniline (11.2 g) was added to milli-Q water (70 mL) and pH was adjusted to 4.6 using 
glacial acetic acid. The final volume was adjusted to 100 mL. The solution was stored at 4 
℃ and filtered with a 0.45 μm sterile filter prior to use. 
 
0.5 M K2CO3 
K2CO3 (6.91 g, anhydrous) was dissolved in 100 mL milli-Q water. 
 
QMA eluent 
Kryptofix222 (237.5 mg) and K2CO3 (42.5 mg) were dissolved in 50 mL acetonitrile and 2 
mL milli-Q water.  
 
5% LiCl 
LiCl (5 g) was dissolved in 100 mL milli-Q water. 
 
6 M NaOH solution 
NaOH (23.99 g) was dissolved in 100 mL milli-Q water 
 
6 M HCl solution 
HCl (37%, 50 mL) was diluted to 100 mL with milli-Q water.  
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0.02 M phosphate buffer (pH 7.4) 
KH2PO4 (68 mg) and K2HPO4 (244 mg) was dissolved in 80 mL of milli-Q water. pH was 
adjusted to 7.4 with phosphoric acid and the solution was diluted to 100 mL with milli-Q 
water. 
 
0.25 M sodium acetate buffer (pH 4.6) 
Sodium acetate (2.051 g) was dissolved in 80 mL of milli-Q water. Glacial acetic acid 
(14.3 mL) was added. pH was adjusted to 4.6 with acetic acid and the solution was diluted 
to 100 mL with milli-Q water. 
 
3.2.2 Chemical synthesis of the precursor and reference compounds 
 
Synthesis of tri-tert-butyl 2,2-dimethyl-4,8,16-trioxo-3,6-dioxa-5,9,15,17-
tetraazaicosane-14,18,20-tricarboxylate (2) 
 
In an oven-dried flask, (Boc-aminooxy)acetic acid (6) (66 mg, 346 µmol, 1.6 eq ) in 0.4 
mL DMF was stirred for 10 minutes. HATU (127 mg, 333 µmol, 1.6 eq) in 0.5 mL DMF 
was added and the mixture was stirred for 15 minutes. Compound 1 (103 mg, 211 µmol, 
1.0 eq) in 0.4 mL DMF was added and the mixture was stirred for 20 minutes. DIPEA (89 
µL, 511 µmol, 2.4 eq) was slowly added into the mixture. The mixture was stirred at room 
temperature in dark for 20 hours under argon atmosphere, and the progression of the reac-
tion was monitored by TLC (ethyl acetate/hexane 3/1 v/v) (figure 16).  
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Figure 16. Optimized synthesis scheme of compound 2. Isolated yield 56% 
 
Upon completion, DMF was removed by liquid-liquid extraction. The reaction mixture 
was diluted with 20 mL ethyl acetate, and the organic phase was washed once with 10 mL 
water, three times with 10 mL 5% LiCl solution, and once with 20 mL brine. The organic 
layer was dried with MgSO4 and concentrated under reduced pressure.  
 
HPLC purification was performed on a semi-preparative Alltima C18 analytical column (5 
µm, 250 mm x 10 mm). The eluting gradient increased from 40/60 acetonitrile/water to 
80/20 after 15 minutes. The flow was kept isocratic for 10 minutes, and lowered back to 
40/60 in 5 minutes. The flow rate was 3 mL/min. Compound 2 eluted at 19.4 min. The 
collected fractions were diluted with water, immobilized into a C18 Sep-Pak cartridge, and 
eluted out with acetonitrile. After solvent removal, 78 mg (117 µmol, 56%) of compound 2 
was isolated as a clear, transparent oil. TLC (ethyl acetate/hexane 3/1 v/v, Rf =0.62). 1H-
NMR (300 MHz, CDCl3) δ 8.11 (s, 1H), 7.91 (bs, 1H), 5.32-5.37 (m, 2H), 4.34 (s, 2H), 
4.24-4.40 (m, 2H) 3.20-3.43 (m, 2H), 2.23-2.40 (m, 2H), 2.01-2.12 (m, 1H), 1.72-1.90 (m, 
2H), 1.49 (s, 9H), 1.46 (s, 9H), 1.45 (s, 9H), 1.44 (s, 9H), 1.22-1.68 (m, 5H). 13C-NMR (75 
MHz, CDCl3) δ 172.81, 172.57, 169.32, 157.89, 157.23, 83.07, 82.20, 81.63, 80.66, 75.96, 
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53.50, 53.10, 38.34, 32.31, 31.74, 28.83, 28.50, 28.28, 28.21, 28.16, 22.23. TOF-ESI-MS 
m/z calcd. for C31H56N4O11 [M+H]+ 661.4018, found 661.3756.  
 
Synthesis of ((5-(2-(aminooxy)acetamido)-1-carboxypentyl)carbamoyl)glutamic acid 
(3) 
 
Compound 2 (26.0 mg, 39.4 µmol) was stirred in 4 mL of TFA/DCM mixture (1/1 v/v) for 
2 hours at room temperature (figure 17). 
 
 
Figure 17. The optimized reaction conditions of intermediate 2 deprotection 
 
The progression of the reaction was monitored by HPLC using a semi-preparative Alltima 
C18 column (5 µm, 250 mm x 10 mm). The eluting gradient increased from 5/95 acetoni-
trile/(water with 0.5% TFA) to 70/30 after 20 minutes at a flow rate of 2 mL/min with 
compound 3 eluting at 10.4 min. Identity of the peak was characterized with TOF-ESI-MS. 
Compound 3 was purified by HPLC with the above conditions. Solvents were removed by 
lyophilization to yield 4.5 mg (11 µmol, 29%) of compound 3 as a white powder. 1H-NMR 
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(300 MHz, D2O) δ 4.65 (s, 2H), 4.29-4.33 (dd, 1H, J = 5.2 Hz, J = 9.2 Hz), 4.22-4.26 (dd, 
1H, J = 5.1 Hz, J = 8.9 Hz), 3.29 (t, 2H, J = 7.0), 2.54 (t, 2H, J = 7.1 Hz), 2.17-2.29 (m, 
1H), 1.98-2.08 (m, 1H), 1.85-1.95 (m, 1H) 1.70-1.81 (m, 1H), 1.57-1.66 (m, 2H), 1.41-
1.51 (m, 2H). TOF-ESI-MS m/z calcd. for C14H25N4O9 [M+H]+ 393.1616, found 393.1640.  
 
Synthesis of 21-fluoro-18,19,20-trihydroxy-5,13-dioxo-15-oxa-4,6,12,16-
tetraazahenicos-16-ene-1,3,7-tricarboxylic acid (4) 
 
5-Fluoro-5-deoxyribose (9) (10.6 mg, 70 µmol, 12.5 eq) was dissolved in 150 µL milli-Q 
water and mixed with compound 3 (2.2 mg, 5.6 µmol, 1.0 eq) in 150 µL milli-Q water. 
The reaction was carried out at room temperature without stirring for 2 hours (figure 18). 
 
 
Figure 18. Reaction conditions used for the oxime formation of compound 3 with [19F]9 to 
yield the product [19F]4 
 
After judged complete, the reaction mixture was purified with HPLC using Alltima C18 
semi-preparative column (5 µm, 250 mm x 10 mm). The eluent system was acetoni-
trile/(0.5% TFA in milli-Q water) (1/1 v/v). The eluting gradient was increased from 5/95 
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to 70/30 over 20 minutes, and lowered back to 5/95 after 10 minutes. The flow rate was 2 
mL/min. Compound 4 eluted at 11.1 min. After the removal of solvents by lyophilization, 
1.2 mg (2.3 µmol, 39%) of compound 4 was isolated as a white powder. 1H-NMR (300 
MHz, D2O) δ 7.74 (d, E-isomer J=6.5 Hz), 7.07 (d, Z-isomer J=6.3 Hz), 4.61 (s, 2H), 4.52-
4.65 (m, 3H), 4.28-4.33 (dd, 1H, J = 5.2 Hz, J = 9.2 Hz), 4.20-4.26 (dd, 1H, J = 5.3 Hz, J = 
8.3 Hz), 3.83-4.12 (m, 2H), 3.29 (t, 2H, J = 7.1 Hz), 2.54 (t, 2H, J = 7.3 Hz), 2.17-2.29 (m, 
1H), 1.98-2.08 (m, 1H), 1.85-1.95 (m, 1H) 1.70-1.81 (m, 1H), 1.55-1.63 (m, 2H), 1.41-
1.49 (m, 2H). TOF-ESI-MS [M+H]+ m/z calcd. for C19H31FN4O12 527.1995 found 
527.1982.  
 
Synthesis of 18-fluoro-19,20,21,22-tetrahydroxy-5,13-dioxo-15-oxa-4,6,12,16-
tetraazadocos-16-ene-1,3,7-tricarboxylic acid (5) 
 
2-Deoxy-2-fluoro-D-glucose (12) (7.4 mg, 40.6 µmol, 4.5 eq) and compound 3 (3.6 mg, 
9.0 µmol) were dissolved in a mixture of methanol (250 µL) and water (500 µL). The reac-
tion mixture was then heated at 85 ℃ for 1 hour without stirring and cooled to room tem-
perature (figure 19). 
 
 
Figure 19. Reaction conditions used for the oxime formation of compound 3 with [19F]12 
to yield the product [19F]5 
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The reaction mixture was purified with HPLC using Alltima C18 semi-preparative column 
(5 µm, 250 mm x 10 mm). The eluent system was acetonitrile/(0.5% TFA in milli-Q water) 
(1/1 v/v). The eluting gradient was increased from 5/95 to 70/30 over 20 minutes, and low-
ered back to 5/95 after 10 minutes. The flow rate was 2 mL/min. Compound 5 eluted at 
10.7 min. After the removal of solvents by lyophilization, 2.0 mg (3.6 µmol, 39%) of com-
pound 5 was isolated as a white powder. 1H-NMR (300 MHz, D2O) δ 7.84 (m, open chain), 
5.35 (m, α anomer), 4.95 (m, β anomer) 4.65 (s, 2H), 3.64-4.33 (m) 3.26 (t, 2H), 2.55 (t, 
2H, J = 7.6 Hz) 2.15-2.27 (m, 1H), 1.96-2.07 (m, 1H) 1.81-1.92 (m, 1H) 1.69-1.79 (m, 
1H), 1.54-1.64 (m, 2H), 1.38-1.49 (m, 2H). TOF-ESI-MS [M-H]- m/z calcd. for 
C19H30FN4O12 555.1839 found 555.1955.  
 
3.2.3 Preparations before radiolabeling 
 
Several preparations with the automated synthesis unit were necessary before starting the 
production of 18F for the radiolabeling reactions. This included adding the correct configu-
ration of valves and syringes to the unit to limit the exposure to high doses of radiation 
during radiolabeling sessions. Pressure-resistant reaction vessels were cleaned with milli-Q 
water and acetone, sonicated and dried in an oven prior to use. The amount of precursor 
utilized was weighted, and a correct amount of solvent was added into each reaction vessel. 
Special ascorbate-filled syringes were also exchanged weekly, and attached into waste vi-
als to trap any volatile radioactive waste produced during the synthesis.  
 
Pretreatment of both quaternary methyl amine- (QMA) and Sep-Pak C-18 cartridges was 
also necessary prior to the start of the synthesis. The QMA cartridge was pretreated with 
10 mL of 0.5 M K2CO3, and washed with 15 mL of milli-Q water. Sep-Pak C-18 cartridges 
were pretreated with 10 mL of ethanol and 10 mL of milli-Q water.  
 
3.2.4 Production of [18F]fluoride 
 
The fluorine-18 in all the radiolabeling reactions in this study was produced with an IBA 
10/5 cyclotron in the facilities of Radiochemistry Unit at the University of Helsinki. Ac-
tivities in the range of 500-2000 MBq were produced with the nuclear reaction 18O[p,n]18F 
by bombarding a target containing 18O (≥ 98%) enriched H218O (IASON GmbH) with ac-
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celerated protons. The loading of the target was checked prior to the bombardment by 
measuring the intake of H218O manually.  
 
An integrated current ranging from 1.0 µAh to 4.0 µAh was utilized in the bombardment, 
with irradiations ranging from 4 minutes to 12, respectively. The cyclotron-produced fluo-
rine-18 was then flushed with helium to a nearby facility containing a lead-shielded fume 
hood and the automated synthesis unit via a lead-shielded and a teflon-coated transfer line. 
However, larger-than-typical currents were used due to the current operational difficulties 
of the cyclotron in question, as only approximately half of the intended activity made it all 
the way to the synthesis unit. The transfer line was typically loaded with H218O again, and 
unloaded to ensure all the activity made it to the synthesis unit, or washed twice with ap-
proximately 0.4 mL of milli-Q water. [18F]fluoride- was then trapped into the QMA car-
tridge while the 18O water was collected into a waste vial. A timer recording the duration 
of the radiosynthesis was started at the end of bombardment, and the radiosynthesis with 
the automated synthesis unit was begun when the QMA cartridge in the dose calibrator 
showed all the activity was present in the system. 
 
3.2.5 Radiosynthesis of 5-[18F]fluoro-5-deoxyribose  
 
The precursor for the radiosynthesis of 5-[18F]fluoro-5-deoxyribose ([18F]9) was laboratory 
made methyl 2,3-O-isopropylidene-5-O-(p-tolylsulfonyl)-beta-D-ribofuranoside (7). After 
successful 18F-labeling, the intermediate [18F]8 was deprotected to yield [18F]9. An over-
view of the synthesis procedure for [18F]9 is shown in figure (20).  
 
 
Figure 20. An overview of the steps involved in the radiosynthesis of 5-[18F]fluoro-5-
deoxyribose ([18F]9) 
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The production of [18F]9 was performed according to the flow chart in figure (21) using an 
automated synthesis unit. 
 
 
Figure 21. Flow-chart of the radiosynthesis scheme used for [18F]9 
 
During the preparations for the radiolabeling session, 6.0 mg (16.7 µmol) of methyl 2,3-O-
isopropylidene-5-O-(p-tolylsulfonyl)-beta-D-ribofuranoside (7) was added into a reaction 
vessel, along with 300 µL of DNA quality acetonitrile. 2 mL of QMA eluent was added 
into a second reaction vessel to elute the trapped [18F]fluoride- into a third reaction vessel. 
500 µL of 6 M HCl was also added into a fourth and final reaction vessel for the removal 
of protecting groups from the intermediate form [18F]8 near the end of the synthesis.  
 
After completing the preparations of the automated synthesis unit, the cyclotron-produced 
[18F]fluoride- that was trapped in the QMA cartridge was eluted into reaction vial 1 (R1) 
with 2 mL of QMA eluent. Reaction vial 1 was heated to 120 ℃ (12 min) and the solvents 
were evaporated with argon gas flow. After cooling the system to room temperature, me-
thyl 2,3-O-isopropylidene-5-O-(p-tolylsulfonyl)-beta-D-ribofuranoside (7), which was 
dissolved in acetonitrile, was moved into reaction vial 1, and the reaction mixture was 
57 
 
heated to 108 ℃ (12 min). The reaction mixture was cooled to room temperature, and 4′-
Dimethoxytrityl chloride (24 mg in 0.5 mL of pyridine) was added. The reaction was car-
ried out for 15 minutes at room temperature, and the mixture was diluted with a 6 M HCl 
(1 mL) and milli-Q water (7 mL). The cloudy liquid was then pushed into a vial, which 
contained 30 mL of milli-Q water.  
 
Next, the diluted reaction mixture was pushed through two Sep-Pak C18 cartridges with 
argon gas. The cartridges were washed with milli-Q water (20 mL), and [18F]8 was eluted 
into reaction vial 2 (R2) with 3 mL of 50% acetonitrile. The protecting groups of the [18F]8 
were removed by heating R2, which contained 500 µL of 6 M HCl to 110 ℃ (12 minutes). 
The reaction mixture was then cooled to room temperature, and subsequently neutralized 
with 6 M NaOH. Purity of [18F]9 was characterized with HPLC using Alltima C18 analyti-
cal column (5 µm, 250 x 4.6 mm). The eluting gradient started from 5/95/0.1 acetoni-
trile/water/trifluoroacetic acid, and was increased to 50/50/0.1 after 15 minutes, and again 
to 70/30/0.1 after 10 minutes. [18F]9 eluted at 3.5 min. 
 
3.2.6 Conjugation of 5-[18F]fluoro-5-deoxyribose with precursor 3 
 
Compound 3 (0.8 mg, 2.0 µmol) was dissolved in 300 µL of 1.2 M anilinium acetate buffer 
(pH 4.6, filtered prior to use). 1 mL of [18F]9 (10.1 MBq) was added to the mixture. The 
reaction was performed at room temperature without stirring for 15 minutes (figure 22).  
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Figure 22. The optimized reaction conditions for oxime formation of compound 3 with 
[18F]9 to yield the product [18F]4. Peptide concentration was 1.5 mM 
 
30 minutes after the start of the reaction, the mixture was subjected to HPLC purification 
using Alltima C18 semi-preparative column (5 µm, 250 mm x 10 mm). The eluent system 
was acetonitrile/(0.5% TFA in milli-Q water) (1/1 v/v). The eluting gradient was increased 
from 5/95 to 70/30 over 20 minutes, and lowered back to 5/95 after 10 minutes. The flow 
rate was 2 mL/min. The peak at 10.5 min was collected to yield 3.09 MBq of [18F]4. The 
purity of [18F]4 was assessed 1 hour after HPLC purification with Alltima C18 analytical 
column (5 µm, 250 x 4.6 mm). The eluting gradient started from 5/95/0.1 acetoni-
trile/water/trifluoroacetic acid (v/v/v), and was increased to 50/50/0.1 after 15 minutes, and 
again to 70/30/0.1 after 10 minutes.  
 
3.2.7 Radiosynthesis of 2-[18F]fluoro-2-deoxy-D-glucose 
 
The precursor for the radiosynthesis of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]12) was 
1,3,4,6–O–Acetyl–2–O–trifluoro-methanesulfonyl–beta–D–mannopyranose (10). After 
successful 18F-labeling, the intermediate [18F]11 was deprotected to yield [18F]12. The ra-
diosynthesis scheme of [18F]12 is summarized in figure (23).  
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Figure 23. An overview of the steps involved in the radiosynthesis of 2-[18F]fluoro-2-
deoxy-D-glucose ([18F]12) 
 
[18F]12 was produced according to the flow-chart in figure (24) using an automated syn-
thesis unit. 
 
 
Figure 24. Flow-chart of the radiosynthesis scheme used for [18F]12 
 
During the preparations for the radiolabeling session, 25 mg (52 µmol) of 1,3,4,6–O–
Acetyl–2–O–trifluoro-methanesulfonyl–beta–D–mannopyranose (10) was added into a 
reaction vessel in 1000 µL of DNA quality acetonitrile. 2 mL of QMA eluent was added 
into a second reaction vessel to elute the trapped [18F]fluoride- into a third reaction vessel. 
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2 mL of 1 M HCl was added into the fourth reaction vessel for immediate neutralization of 
[18F]12 after the removal of protecting groups. 
 
After completing the preparations of the automated synthesis unit, the cyclotron-produced 
[18F]fluoride- was trapped in the QMA cartridge, and was eluted into reaction vial 1 (R1) 
with 2 mL of QMA eluent. Reaction vial 1 was heated to 120 ℃ (10 min) and the solvents 
were evaporated with argon gas flow. After cooling the system to room temperature, 
1,3,4,6–O–Acetyl–2–O–trifluoro-methanesulfonyl–beta–D–mannopyranose (10), which 
was dissolved in acetonitrile, was pushed into reaction vial 1, and the reaction mixture was 
heated to 85 ℃ (5 min). The reaction mixture was diluted with 4 mL of milli-Q water and 
pushed through Sep-Pak C18 cartridge. The process was repeated with another 4 mL of 
milli-Q water. Next, the C18 cartridge was washed with 10 mL of milli-Q water. 2 mL of 1 
M NaOH was pushed through the cartridge slowly, and the cartridge was washed with 1 
mL of milli-Q water. The reaction mixture was neutralized by 2 mL of 1 M HCl, which 
was already in the reaction vessel. 
 
Purity of [18F]12 was characterized with HPLC using Alltima C18 semi-preparative col-
umn (5 µm, 250 mm x 10 mm). The eluent system was acetonitrile/(0.5% TFA in milli-Q 
water) (1/1 v/v). The eluting gradient was increased from 5/95 to 70/30 over 20 minutes, 
and lowered back to 5/95 after 10 minutes. The flow rate was 2 mL/min. [18F]12 eluted at 
6.2 min. 
 
3.2.8 Conjugation of 2-[18F]fluoro-2-deoxy-D-glucose with precursor 3 
 
Compound 3 (1.3 mg, 3.3 µmol) was dissolved in 100 µL of methanol. 200 µL of [18F]12 
(7.8 MBq) was mixed with 40 µL of aniline, and added into the vial with compound 3. The 
mixture was heated at 85 ℃ for 30 minutes (figure 25).  
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Figure 25. The reaction conditions for oxime formation of compound 3 with [18F]12 to 
yield the product [18F]5. Peptide concentration of 9.8 mM was used 
 
After cooling to room temperature, 0.8 mL of 0.25 M sodium acetate buffer (pH 4.7) was 
added to the mixture. The presence of [18F]5 was confirmed with HPLC using Alltima C18 
semi-preparative column (5 µm, 250 mm x 10 mm). The eluent system was acetoni-
trile/(0.5% TFA in milli-Q water) (1/1 v/v). The eluting gradient was increased from 5/95 
to 70/30 over 20 minutes, and lowered back to 5/95 after 10 minutes. The flow rate was 2 
mL/min. The radioactive peak of [18F]5 was detected at 11.9 min. Viability of HPLC puri-
fication of [18F]5 was demonstrated by purifying a small fraction (100 µL) of the reaction 
mixture to yield 0.126 MBq of purified [18F]5. Purity and stability of [18F]5 was confirmed 
2 hours after HPLC purification using the same conditions.  
 
3.2.9 Determination of lipophilicity 
 
LogD7.4 values were determined for both [18F]4 and [18F]5 by a modified shake-flask 
method.158 20 µL of HPLC-purified [18F]4 or 100 µL of HPLC-purified [18F]5 was added 
into a separating funnel with 10 mL of 1-octanol and 10 mL of 0.02 M phosphate buffer 
(pH 7.4). The funnel was shaken vigorously, the organic phase was disposed, and the pro-
cess was repeated once more with 10 mL of 0.02 M phosphate buffer (pH 7.4). 2 mL of the 
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water-soluble phase was added into 4 separate falcon tubes with 2 mL of 1-octanol in each. 
The tubes were shaken for 10 minutes and centrifuged for 5 minutes at 1000 g. 500 µL 
samples were taken from the upper (1-octanol) and lower (phosphate buffer) phases, and 
added into separate, pre-weighted tubes. The activity of the samples was measured with a 
gamma counter.  
 
3.2.10 Equations 
 
Decay corrections for the activities of the radionuclides were calculated with equation (1) 
 
𝐴 = 𝐴଴ ∙ 2
ି ೟೟భ/మ,              (1) 
 
Where  
A = activity at time point t (MBq) 
A0 = activity at the start of the reaction (MBq) 
t = elapsed time (h) 
t1/2 = half-life of the radionuclide in question (h)  
 
The decay-corrected yield (DCY) of the radiosynthesis product was calculated with equa-
tion (2) 
 
𝐷𝐶𝑌 = ஺బ (௣௥௢ௗ௨௖௧)
஺బ (ொெ஺)
∙ 100 %,              (2) 
 
Where  
A0 (product) = decay-corrected activity of the labeled product (MBq) 
A0 (F-18) = The initial activity immobilized in the QMA cartridge (MBq) 
 
For the calculation of logD7.4 values, an average value of counts was calculated with equa-
tion (3). 
 
𝐴௔௩௚ =
஺భା⋯ା஺೙
௡
,              (3) 
Where 
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A1 = counts of the first sample 
An = counts of the sample number n 
n = number of samples 
 
The standard deviation of the measured counts was obtained with equation (4) 
 
𝑠 =  ට
∑ ൫஺೙ି஺ೌೡ೒൯
మ೙
೔సభ
௡ିଵ
,              (4) 
 
Where  
An = counts of the sample number n 
Aavg = average value of counts of the sample 
n = number of samples 
 
The distribution coefficient (logD7.4) was calculated using equation (5) 
 
𝐷଻.ସ =
(௖௢௨௡௧௦ /௚ ௜௡ ௢௖௧௔௡௢௟)
(௖௢௨௡௧௦ /௚ ௜௡ ௕௨௙௙௘௥)
= ோ೚೎೟ೌ೙೚೗
ோ್ೠ೑೑೐ೝ
,             (5) 
 
Where 
Roctanol = counts per gram in 1-octanol phase 
Rbuffer = counts per gram in 0.02M phosphate buffer phase (pH 7.4) 
 
The uncertainty of the distribution coefficient (logD7.4) was calculated with equation (6) 
 
∆𝐷଻.ସ = ඪ
ቀ డ஽ళ.ర
డோ೚೎೟ೌ೙೚೗
∙ ∆𝑅௢௖௧௔௡௢௟ቁ
ଶ
+ ൬ డ஽ళ.ర
డோ್ೠ೑೑೐ೝ
∙ ∆𝑅௕௨௙௙௘௥൰
ଶ,             (6) 
= ඩቆ
∆𝑅௢௖௧௔௡௢௟
𝑅௕௨௙௙௘௥
ቇ
ଶ
+ ൭−
∆𝑅௕௨௙௙௘௥ ∙  𝑅௢௖௧௔௡௢௟
൫𝑅௕௨௙௙௘௥൯
ଶ ൱
ଶ
 
 
Where 
∆Roctanol = standard deviation of counts per gram in 1-octanol phase 
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∆Rbuffer = standard deviation of counts per gram in 0.02 M phosphate buffer phase 
Roctanol = counts per gram in 1-octanol phase 
Rbuffer = counts per gram in 0.02 M phosphate buffer phase 
 
The uncertainty of the LogD7.4 value was calculated with equation (7) 
 
∆𝑙𝑜𝑔𝐷଻.ସ = ටቀ
డ௟௢௚஽ళ.ర
డ஽ళ.ర
∙ ∆𝐷଻.ସቁ
ଶ
=  ටቀ୪୭୥ (௘)
஽ళ.ర
∙ ∆𝐷଻.ସቁ
ଶ
,             (7) 
Where 
D7.4 = distribution coefficient at pH 7.4 
∆D7.4 = uncertainty of the distribution coefficient at pH 7.4 
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3.3 Results and discussion 
 
3.3.1 Synthesis of the precursor 
 
The first part of the project involved the synthesis of the precursor 3 moiety of the PSMA 
inhibitor. This was achieved in two parts. First, by synthesizing intermediate 2 by conju-
gating compound 1 with compound 6 (figure 16), followed by the removal of three tert-
butyl ester groups and one Boc-protecting group via acid-catalyzed deprotection (figure 
17). 
 
Synthesis of intermediate 2 was achieved via an amide coupling reaction. The reaction was 
catalyzed with an aminium salt, HATU ((1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), which was utilized to generate an 
active ester compound 6. This was further catalyzed by the presence of a Hünig's base, 
DIPEA (N,N-diisopropylethylamine). Reaction time was varied between 5.5 – 22 hours, 
with best yield (56%) obtained by an overnight reaction time. Two major modification 
were performed during the optimization attempts. First, by decreasing the concentration of 
HATU from 1.8 equivalents to 1.6 equivalents, and second, by increasing the reaction time 
from 5.5 hours to 20 hours.  
 
The purification of compound 2 was initially attempted with a silica column using di-
chloromethane/methanol as the solvent system (1/1, 2/1 or 9/1 v/v). Fractions containing 
compound 2 were identified with Advion expression CMS atmospheric pressure chemical 
ionization/atmospheric solids analysis probe (APCI/ASAP). The mass spectra indicated the 
presence of an ion with mass-to-charge ratio of 661.7, which corresponded well with the 
expected protonated (M+H+) peak of compound 2 (661.39 m/z). However, subsequent 
HPLC analysis of fraction 3 indicated the presence of multiple impurities, which silica 
column purification was unable to remove with the chosen eluent system. Thus, the purifi-
cation was performed with HPLC.  
 
Characterization of compound 2 was performed with 1H-NMR (attachment 1), 13C-NMR 
(attachment 2) and TOF-ESI-MS (attachment 3). Analysis by TOF-ESI-MS showed that 
the obtained m/z value of 661.3757 [M+H]+ was close to the calculated m/z of 661.4018 
[M+H]+ of compound 2. The presence of adduct peaks of sodium 683.3575 [M+Na]+ and 
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potassium 699.3315 [M+K]+ was also evident. The 1H-NMR spectrum also showed 4 char-
acteristic singlets at 1.44 ppm, 1.45 ppm, 1.46 ppm and 1.49 ppm, which were to be ex-
pected with a compound containing tert-butyl groups with almost identical chemical envi-
ronments (figure 26). All carbons shown in the 13C-NMR spectrum were also identified. 
The chemical shifts in the 13C-NMR spectrum also corresponded well with expectations, 
with chemical shifts relating to of all the five carbonyl groups (C=O) identifiable (157.23 
ppm, 169.32 ppm, 172.57 ppm, 172.57 ppm, 172.81 ppm) at high chemical shifts. Fur-
thermore, the obtained results corresponded well with the results published by another 
group,120 with a similar obtained mass (661.40), and the same chemical shifts as shown in 
figure (26), including the four tert-butyl groups with similar chemical shifts (1.41 ppm, 
1.43 ppm, 1.44 ppm and 1.46 ppm). Interestingly, the same group also succeeded in per-
forming the purification with a silica column, using a different eluent system (ethyl ace-
tate/hexane 1/1). 
 
 
1H NMR (300 MHz, CDCl3) δ 8.11 (s, 1H, H-5), 7.91 (bs, 1H, H-7), 5.32-5.37 (m, 2H, H-13, H-14), 4.34 (s, 
2H, H-6), 4.24-4.40 (m, 2H, H-12, H-15), 3.20-3.43 (m, 2H, H-8), 2.23-2.40 (m, 2H, H-17), 2.01-2.12 (m, 
1H, H-16), 1.72-1.90 (m, 2H, H-11), 1.49 (s, 9H, R2a-c), 1.46 (s, 9H, R3a-c), 1.45 (s, 9H, R4a-c), 1.44 (s, 
9H, R1a-c), 1.22-1.68 (m, 5H, H-9, H-10). 
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13C NMR (75 MHz, CDCl3) δ 172.81 (C-27), 172.57 (C-13, C-20), 169.32 (C-7), 157.89 (C-18), 157.23 (C-
5), 83.07 (C-4), 82.20 (C-14), 81.63 (C-21), 80.66 (C-28), 75.96 (C-6), 53.50 (C-12), 53.10 (C-19), 38.34 (C-
8), 32.31 (C-11, C-26), 31.74 (C-9), 28.83 (C-29, C-30, C-31), 28.50 (C-22, C-23, C-24), 28.28 (C-15, C-16, 
C-17), 28.21 (C-1, C-2, C-3), 28.16 (C-25), 22.23 (C-10). 
Figure 26. NMR interpretation of tri-tert-butyl 2,2-dimethyl-4,8,16-trioxo-3,6-dioxa-
5,9,15,17-tetraazaicosane-14,18,20-tricarboxylate (2) 
 
The removal of protecting groups from intermediate 2 proved to be more challenging than 
expected. The reasons for this were two-fold: First, the previously rapid and trustworthy 
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detection by MS (APCI/ASAP) proved to be unsuitable for the compound with exposed 
carboxylic acid residues, and second, the precursor 3 moiety seemed to be unstable in a 
highly acidic environment – a necessity for most deprotection protocols involving Boc-
protecting group. Thus, a more thorough investigation of the literature was necessary to 
proceed further. 
 
The removal of tert-butoxycarbonyl groups is typically done with a mixture of trifluoroace-
tic acid (TFA) and dichloromethane (DCM) (1:1) with a widely ranging reaction times, 
typically within 2-16 hours,159 depending on the compound. Deprotection with 100% TFA 
has also been successfully achieved with some compounds with fast reaction times.159 Se-
lective deprotection of Boc-protecting group has also been done with 4 M HCl in dioxane 
in 30 minutes at room temperature, and also with 1 M HCl in ethyl acetate in 3-5 hours at 
room temperature.160,161 Selective deprotection of tert-butyl esters has also been achieved 
with ZnBr2 in DCM when other acid-labile groups, such as Boc were present.162,163 A mild 
deprotection with aqueous phosphoric acid (85%) has also been achieved.164  
 
Eventually, two deprotection agents were discovered that showed promise: 2 M HCl in 
diethyl ether and DCM/TFA mixture (1/1 v/v). Initially, deprotection of the intermediate 
was performed with 2 M HCl in diethyl ether as the deprotection agent with an overnight 
reaction time. Formation of insoluble precipitate, thought to be compound 3, was evident. 
However, the formation of multiple unintended by-products was evident when subjecting 
the compound to rotary evaporation, even when using low heat. Even without rotary evap-
oration, the compound seemed to degrade over time in an acidic environment, indicating a 
shorter reaction times should be used. 
 
A study was published during the scope of this thesis by another research group.120 The 
group utilized trifluoroacetic acid/dichloromethane (1/1 v/v) as the deprotection agent. The 
deprotection was performed at room temperature in 3 hours to obtain compound 3 with a 
73% yield after purification by HPLC and removal of solvents. The good results by the 
group inspired another attempt to improve the deprotection method of the compound. 
 
The same deprotection agent was utilized, and the progression of the reaction was moni-
tored by HPLC by taking a sample hourly. The reaction seemed to reach completion at 2 
hours, with minor degradation of the 10.4 min peak observable after 2 hours. To avoid the 
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observed degradation of the compound, only small volume of the deprotection agent was 
used to avoid the concentration step by rotary evaporation altogether. HPLC Chromato-
gram of the mixture indicated the compound at 10.4 min had stayed largely intact, and 
fractions of the compound were collected. The removal of solvents was performed by im-
mediately subjecting the compound to lyophilization.  
 
The stability and identity of compound 3 with this patch was assessed by 1H-NMR (at-
tachment 4), and TOF-ESI-MS (attachment 5). The 1H-NMR spectrum indicated that the 4 
characteristic singlets belonging to the four tert-butyl groups of compound 2 had disap-
peared (figure 27). This, however, was not enough to draw conclusions on the correct 
structure of the molecule, as these singlets had disappeared with almost all the deprotection 
attempts that were done previously. Nevertheless, this attempt provided the first clean 1H-
NMR spectrum, where there were no unidentifiable peaks in the 1.8-2.0 ppm region. Also, 
analysis of the batch by HPLC after lyophilization indicated that the collected compound 3 
had stayed intact for the first time. Unfortunately, no 13C-NMR of the compound was ob-
tained due to the small amount of sample. Still, the obtained 1H-NMR spectrum does pro-
vide some clues about the structure of the molecule, as can be seen from the singlet at 4.65 
ppm belonging to hydrogens 15a and 15b. The chemical shifts at 4.29-4.33 ppm and 4.22-
4.26 also correspond well with hydrogens 4 and 8, respectively, with their chemical envi-
ronment manifesting as a doublet of doublet with J-coupling values of 5.2 and 9.2 Hz (H-
4) or 5.1 and 8.9 Hz (H-8). Additionally, hydrogens 2 and 13 show their characteristic tri-
plets at 2.54 ppm and 3.29 ppm with J-coupling values of 7.1 Hz and 7.0 Hz, respectively. 
As can be expected, the rest of the hydrogens in the spectrum were found as multiplets due 
to their complex environment in the 1.41-2.29 ppm region.  
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1H-NMR (300 MHz, D2O) δ 4.65 (s, 2H, H-15), 4.29-4.33 (dd, 1H, J = 5.2 Hz, J = 9.2 Hz, H-4), 4.22-4.26 
(dd, 1H, J = 5.1 Hz, J = 8.9 Hz, H-8), 3.29 (t, 2H, J = 7.0 Hz, H-13), 2.54 (t, 2H, J = 7.1 Hz, H-2), 2.17-2.29 
(m, 1H, H-3b), 1.98-2.08 (m, 1H, H-3a), 1.85-1.95 (m, 1H, H-10a) 1.70-1.81 (m, 1H, H-10b), 1.57-1.66 (m, 
2H, H-12), 1.41-1.51 (m, 2H, H-11). 
Figure 27. NMR interpretation of ((5-(2-(aminooxy)acetamido)-1-
carboxypentyl)carbamoyl)glutamic acid (3) 
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The best confirmation of the identity of the molecule was obtained with TOF-ESI-MS, 
where a compound with m/z ratio of 393.1640 [M+H]+ was found. This corresponded well 
with the calculated m/z ratio of 393.1616. As with compound 2, the adduct peaks for sodi-
um 415.1419 [M+Na]+ and potassium at 431.1188 [M+K]+ were present.  
 
Interestingly, the yield of the reaction remained low (29%) compared to the results ob-
tained by Bouvet et al (2017) due to unclear reasons (73%).120 One possible reason for this 
might be due to the nature of lyophilization process as the mixture contained both acetoni-
trile and TFA instead of pure water. It should also be noted that due to the nature of the 
carboxylic acid residues of the precursor it likely exists as a TFA salt. This can have a neg-
ative effect on some experiments, including in vivo cell assays, Fourier-transform infrared 
(FTIR) spectroscopy (strong IR absorption band), or it can cause inaccuracies in the true 
weight of the peptides.165 TFA can be removed by adding a stronger acid (HCl) and lyophi-
lizing the mixture, or by methods, such as HPLC or ion-exchange chromatography.166 Al-
so, in addition to the 1H-NMR analysis, 13C-NMR analysis should be performed to gain 
confirmation of the purity of the sample. 13C-NMR analysis of precursor 3 was not 
achieved due to the small amount of sample when a working purification method was fi-
nally achieved.  
 
Based on the observed results, it was concluded that rotary evaporation is completely un-
suitable for the compound in question. Literature review of the reasons behind the com-
pound degradation yielded little support. However, Kelly et al. (2017) described an unex-
pected acid-catalyzed degradation during the deprotection of some of the alkyne precursors 
of the PSMA inhibitors under investigation.109 The group concluded some of the com-
pounds were unstable towards acidic deprotection. This was supported by the findings in 
this thesis as well, as the formation of multiple compounds with differing retention times 
was evident with long reaction times in both 50% TFA and in 2 M HCl. Also, the pep-
tidomimetic structure of the precursor was likely at fault also, as certain peptides are noto-
riously unstable in acidic environments.  
 
3.3.2 Synthesis of the reference compounds 
 
Oxime formation of compound 3 was attempted with two carbohydrates: 5-fluoro-5-deoxy-
ribose ([19F]9) and 2-fluoro-2-deoxy-D-glucose ([19F]12). The synthesis of [19F]4 was 
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achieved successfully in 3 hours at room temperature (39% yield) in water. The conjuga-
tion was successful without any catalyzing agent. However, this led to a low yield. Thus, to 
improve the yield and to decrease the reaction time, a catalyzing agent, such as anilinium 
acetate buffer (pH 4.6, 0.3 M) should be utilized, assuming the separation of the compound 
from aniline is successful with their similar retention times. This can likely be achieved 
with the same HPLC method as described in the radiosynthesis of [18F]9 with a <1 min 
difference in the retention time of compound 4 and aniline, but not with the other methods 
used in this thesis.  
 
HPLC purification and subsequent lyophilization provided [19F]4 with acceptable purity, 
confirmed by 1H-NMR (attachment 6). Identity of the compound was confirmed with 
TOF-ESI-MS (attachment 7). TOF-ESI-MS spectrum indicated the presence of a com-
pound with m/z ratio of 527.1982 [M+H]+. This corresponded well with the calculated m/z 
ratio of 527.1995 for [19F]4. The presence of sodium adduct at 549.1782 [M+Na]+ and po-
tassium adduct at 565.1456 [M+K]+ was also evident. 
 
1H-NMR spectrum proved to be similar to that of compound 3, with the same multiplets in 
the 1.41-2.29 ppm region present (figure 28). Additionally, the same singlet at 4.62 ppm, 
the two doublet of doublets at 4.28-4.33 ppm and 4.20-4.26 ppm, and the triplets at 3.29 
ppm and 2.54 ppm were also observed in the spectrum. Two doublets at 7.74 ppm and 7.07 
ppm were also observed, likely belonging to the E- and Z -isomers of compound 4 (J-
coupling 6.5 Hz and 6.3 Hz, hydrogen-16). New multiplets were also identified at 4.52-
4.65 ppm and 3.83-4.12 ppm, likely resulting from the hydrogens of the conjugated carbo-
hydrate. However, the presence of an uncharacterized singlet at 3.4 ppm was also evident 
in the spectrum, indicating that the product was not completely pure, and thus, 13C-NMR 
should be performed. 
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1H-NMR (300 MHz, D2O) δ 7.74 (d, E-isomer J=6.5 Hz, H-16), 7.07 (d, Z-isomer J=6.3 Hz, H-16), 4.61 (s, 
2H, H-15), 4.52-4.65 (m, 3H, H-23), 4.28-4.33 (dd, 1H, J = 5.2 Hz, J = 9.2 Hz, H-4), 4.20-4.26 (dd, 1H, J = 
5.3 Hz, J = 8.3 Hz, H-8), 3.83-4.12 (m, 2H, H-17, H-21), 3.29 (t, 2H, J = 7.1 Hz, H-13), 2.54 (t, 2H, J = 7.3 
Hz, H-2), 2.17-2.29 (m, 1H, H-3b), 1.98-2.08 (m, 1H, H-3a), 1.85-1.95 (m, 1H, H-10a) 1.70-1.81 (m, 1H, H-
10b), 1.55-1.63 (m, 2H, H-12), 1.41-1.49 (m, 2H, H-11). 
Figure 28. NMR interpretation of 21-fluoro-18,19,20-trihydroxy-5,13-dioxo-15-oxa-
4,6,12,16-tetraazahenicos-16-ene-1,3,7-tricarboxylic acid (4) 
 
Conjugation of compound 3 with the second carbohydrate, 2-fluoro-2-deoxy-D-glucose 
([19F]5), was also attempted. Due to the electronegative fluorine at carbon-2, harsher reac-
tion conditions were utilized to ensure the presence of the aldehyde form of the carbohy-
drate. The conjugation was achieved successfully by utilizing heat (85 ℃) and a long reac-
tion time (1 hour) in a mixture of methanol/water (1/2, v/v). Due to the lack of a purifica-
tion method for compound 3 at the time of the synthesis, unpurified compound 3 was uti-
lized. Thus, to get a better insight into the success of the reaction, the synthesis could be 
repeated with purified compound 3. The reaction time could also be decreased by utilizing 
a catalyzing agent, such as aniline. 
 
After purification by HPLC and subsequent lyophilization, identity of [19F]5 was con-
firmed by 1H-NMR (attachment 8) and TOF-ESI-MS (attachment 9). TOF-ESI-MS spec-
trum indicated the presence of a compound with m/z ratio of 555.1955 [M-H]-. This corre-
sponded well with the calculated m/z ratio of 555.1839 for [19F]5. 
 
The same chemical shifts belonging to the hydrogens of compound 3 were present 1H-
NMR-spectrum (figure 29), as with compound 4. This included the singlet at 4.65 min, the 
triplets at 3.26 ppm and 2.54 ppm, and the multiplets in the region 1.38-2.27. The two dou-
blet of doublets were likely present as well, but the region likely contained some overlap-
ping with the hydrogens from the carbohydrate structure. The chemical shifts at 7.84 ppm 
(open chain), 5.35 ppm (𝛼 anomer), and 4.95 ppm (𝛽 anomer) likely resulted from the dif-
ferent isomers of the carbohydrate. However, the small amount of sample made a more 
thorough analysis difficult, as the fine structure of the spectrum was unclear. Still, the 
chemical shifts of the anomers of the carbohydrate corresponded well with the NMR anal-
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ysis of the same compound, published by another group,120 where the same signals were 
observed at 7.77 ppm, 5.41 ppm and 4.87 ppm for open chain, 𝛼 anomer, and 𝛽 anomer, 
respectively. As previously, 13C-NMR should be performed to gain further confirmation 
about the identity of the compound. 
 
 
1H-NMR (300 MHz, D2O) δ 7.84 (m, open chain, H-16), 5.35 (m, 𝛼 anomer, H-16), 4.95 (m, 𝛽 anomer, H-
16) 4.65 (s, 2H, H-15), 3.64-4.33 (m, H-4, H-8 H-18, H-17, H-21, H-22, H-24, H-25), 3.26 (t, 2H, H-13), 
2.55 (t, 2H, J = 7.6 Hz, H-2) 2.15-2.27 (m, 1H, H-3b), 1.96-2.07 (m, 1H, H-3a) 1.81-1.92 (m, 1H, H-10a) 
1.69-1.79 (m, 1H, H-10b), 1.54-1.64 (m, 2H, H-12), 1.38-1.49 (m, 2H, H-11). 
Figure 29. NMR interpretation of 18-fluoro-19,20,21,22-tetrahydroxy-5,13-dioxo-15-oxa-
4,6,12,16-tetraazadocos-16-ene-1,3,7-tricarboxylic acid (5) 
 
3.3.3 Radiosynthesis of 5-[18F]fluoro-5-deoxyribose and oxime formation with pre-
cursor 3 
 
The radiosynthesis of [18F]4 was a two-step process. The first step involved attempts at 
optimizing the synthesis of [18F]9 (figure 20), and second step involved attempts to opti-
mize the conditions for oxime ether formation (figure 22). The first part was performed in 
a semi-automated synthesis unit (figure 21), while the oxime ether formation was per-
formed manually. The precursor of [18F]9 was methyl 2,3-O-isopropylidene-5-O-(p-
tolylsulfonyl)-beta-D-ribofuranoside (7), which had been synthesized in-house by a previ-
ously published method.136 It contained tosylate as the leaving group to enable the SN2 
radiofluorination reaction.  
 
Completion of the fluorination step was confirmed with HPLC by taking a sample from R1 
after cooling back to room temperature. Fluorination was performed at 108 ℃ with a reac-
tion time of ranging from 8-12 minutes. The initial radiolabeling sessions with 8 min label-
ing time had a larger quantity of impurities present in the product vial of [18F]9 so the la-
beling time was increased to 12 min with subsequent radiolabeling sessions. 
 
The original aim of the radiosynthesis of [18F]9 in this thesis was to perform it without a 
HPLC purification step that typically follows deprotection. The first part of this involved 
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the addition of 4,4′-Dimethoxytrityl chloride (DMT-Cl) in pyridine into R1 after successful 
fluorination of compound 7 to yield [18F]8. The additional step of DMT-Cl was used to 
remove the carbohydrate precursor and its hydroxylation product. 4,4′-Dimethoxytrityl 
chloride is a commonly used reagent as a protecting group of hydroxides. Due to its lipo-
philic nature, it was easily immobilized in the C18 cartridge, while [18F]8 eluted out with 
50% acetonitrile into R2. 
 
Deprotection of the [18F]8 to yield the final product [18F]9 was performed by heating the 
reaction mixture in the presence of a strong acid (HCl) to 110 ℃ for 12-20 minutes. No 
major differences were found by varying the temperature. Thus, 12 min was deemed satis-
factory. A sample from R2 was taken prior to neutralization to confirm the presence of 
[18F]9. A possible UV signal of [18F]9 was detected with a retention time of 3.399 min at 
wavelength 209 nm (figure 30). However, due to the lack of apparent UV absorbance of 
the compound, the signal at retention time 3.399 min might belong to another unspecified 
compound. The Radio-HPLC chromatogram indicated the presence of a single peak at 3.51 
min (figure 31) with a radiochemical purity of 99% indicating that the synthesis of [18F]9 
had been successful. Radio-TLC was not included for [18F]9 due to unreliability of the elu-
ent system, as the result couldn’t be replicated. 
 
 
Figure 30. HPLC chromatogram of reaction vial 2 after deprotection and prior to neutrali-
zation. UV detection with wavelength 209 nm. The sample was analyzed with Alltima C18 
analytical column (5 µm, 250 x 4.6 mm). The eluting gradient started from 40/60/0.1 ace-
tonitrile/water/TFA, and was increased up to 80/20/0.1 after 20 minutes. The flow rate was 
1 mL/min 
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Figure 31. Radio-HPLC chromatogram of reaction vial 2 after the deprotection of [18F]9 
intermediate [18F]8, and prior to neutralization. Radiochemical purity of [18F]9 was 99%. 
The sample was analyzed with Alltima C18 analytical column (5 µm, 250 x 4.6 mm). The 
eluting gradient started from 40/60/0.1 acetonitrile/water/TFA, and was increased up to 
80/20/0.1 after 20 minutes. The flow rate was 1 mL/min 
 
The best radiochemical yield obtained for [18F]9 was 34% (172 MBq) when decay-
corrected to the end of bombardment (EOB). The total synthesis time was 2.9 hours start-
ing from the end of bombardment, and ending at the neutralization step. The decay correc-
tion was calculated with equation (1). 
 
Thus, when the measured activity of [18F]9 was 30.77 MBq at 4.2 h, the initial activity was 
 
𝐴଴ =
஺
ଶ
ష ೟೟భ/మ
=  ଷ଴.଻଻ ெ஻௤
ଶష
ర.మయయ ೓
భ.ఴవఱ ೓
= 144.731 𝑀𝐵𝑞 = 145 𝑀𝐵𝑞. 
 
The DCY of [18F]9 was then calculated with equation (2) 
 
Thus, when the initial activity of [18F]F- in the QMA cartridge (corrected to EOB) was 
502.94 MBq, the decay-corrected yield (DCY) of the synthesis was 
 
𝐷𝐶𝑌 = ஺బ (ி஽ோ)
஺బ (ிିଵ଼)
∙ 100% =  ଵସସ.଻ଷଵ ெ஻௤
ହ଴ଶ.ଽସ ெ஻௤
∙ 100% = 27.777% = 28%. 
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The biggest loss of radioactivity during the optimization process happened mainly during 
the Sep-Pak C18 purification step. Immobilization of activity into C18 cartridge was espe-
cially significant, indicating the elution strength (or volume) of 50% acetonitrile likely 
wasn’t sufficient. Also, during some syntheses, up to 30% of activity remained in the 
QMA cartridge, likely due to the drying of the cartridge prior to elution.  
 
After the synthesis of [18F]9, an attempt was made to conjugate it with compound 3 via 
oxime ether formation in order to synthesize the [18F]FDR ([18F]9) conjugated PSMA in-
hibitor, [18F]4. The reaction was performed at room temperature by varying the reaction 
time from 5 minutes to 60 minutes. However, the results obtained by radio-TLC couldn’t 
be replicated, so the earliest time point available for a reliable measurement by HPLC was 
at 15 minutes. 1.2 M anilinium acetate buffer was added into the vial with compound 3, so 
that the concentration in the solution was 0.3 M. The best result was obtained with 15 min 
reaction time with a peptide concentration of 1.5 mM (figure 22).  
 
A sample from the reaction mixture was analyzed at 15 minutes with HPLC. The radio-
labeling of [18F]4 proved to be highly efficient and specific, yielding the product [18F]4 
with a radiolabeling yield of 91% (figure 32).  There was no indication of a competing by-
product formation, and the only impurities resulted from an uncharacterized peak at 2.7 
min, and from the peak of unreacted [18F]9 at 3.5 min. 
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Figure 32. Radio-HPLC chromatogram. Oxime formation of precursor 3 with [18F]9 to 
yield the product [18F]4. Sample taken at 15 minutes. Peak at 6.94 min corresponds to 
[18F]4 with a radiolabeling yield of 91% prior to purification. The sample was analyzed 
with Alltima C18 analytical column (5 µm, 250 x 4.6 mm). The eluting gradient started 
from 40/60/0.1 acetonitrile/water/TFA, and was increased up to 80/20/0.1 after 20 minutes. 
The flow rate was 1 mL/min 
 
Initially, the purification of [18F]4 was attempted with a combination of Sep-Pak C-18 car-
tridge to remove excess [18F]9, and aminolink™ resin to remove unreacted compound 3. 
The reaction mixture containing [18F]4 was diluted from 1.33 mL to 20 mL with milli-Q 
water. The mixture was pushed through a single Sep-Pak C18 cartridge, washed once with 
30 mL milli-Q water, and the product was eluted out with 1 mL of 50% acetonitrile. Most 
of the product eluted out during the washing step, indicating either the dilution of the orig-
inal sample was insufficient, or that the washing volume was too large. As a result, the 
dilution was increased to 30 mL milli-Q water, and the washing volume decreased to 12 
mL. The purification with the improved method proved unsuitable as majority of the ac-
tivity had washed out during the washing step again. Additionally, two uncharacterized 
chemical impurities remained in the product fraction after purification with this method.  
 
Thus, purification of [18F]4 was performed with HPLC in the subsequent experiments uti-
lizing a semi-preparative column, equipped in one of the hot cells. The entire batch was 
subjected to HPLC purification, yielding 3.09 MBq of [18F]4.  
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The purity of [18F]4 was assessed 1 hour after purification with HPLC by UV detection 
(figure 33) and radioactive detection (figure 34). The UV detection at wavelength 209 nm 
indicated the presence of two peaks with retention times of 6.12 min and 6.78 min. The 
peak at 6.12 min corresponded well with the retention time of compound 3, and the peak at 
6.78 min with both [18F]4 and aniline. Due to the large signal, the latter peak likely be-
longed to aniline despite the HPLC purification. This can be explained by the small differ-
ence in the retention times of the compounds with the used purification method, where a 
large UV signal of aniline was observed right by the radioactive peak of [18F]4 (attachment 
10). This indicates that the product mixture likely contained some aniline as an impurity. 
The radio-HPLC chromatogram in figure (34) suggests that the radiochemical impurities 
were largely removed by the purification method, with only a small impurity signal from 
[18F]9 remining. Thus, the product [18F]4 was obtained with a radiochemical purity of 98%, 
but likely containing compound 3 and aniline as the chemical impurities. 
 
 
Figure 33. HPLC chromatogram of [18F]4 after HPLC purification. UV detection with 
wavelength 209 nm. Sample taken 1 hour after HPLC purification [18F]4. A signal belong-
ing to compound 3 (6.1 min, 15%), and to the product [18F]4 and aniline (6.8 min, 85%) 
were observed. The sample was analyzed with Alltima C18 analytical column (5 µm, 250 
x 4.6 mm). The eluting gradient started from 40/60/0.1 acetonitrile/water/TFA, and was 
increased up to 80/20/0.1 after 20 minutes. The flow rate was 1 mL/min 
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Figure 34. Radio-HPLC chromatogram of [18F]4 after HPLC purification. Radiochemical 
purity of (98%) was achieved with this method. Minor signal of [18F]9 was observed at 
retention time 3.5 min 1 hour after purification, likely due to the degradation of [18F]4. The 
sample was analyzed with Alltima C18 analytical column (5 µm, 250 x 4.6 mm). The elut-
ing gradient started from 40/60/0.1 acetonitrile/water/TFA, and was increased up to 
80/20/0.1 after 20 minutes. The flow rate was 1 mL/min 
 
3.3.4 Radiosynthesis of 2-[18F]fluoro-2-deoxy-D-glucose and oxime formation with 
precursor 3 
 
The radiosynthesis of [18F]5 was a two-step process. The first step involved attempts at 
optimizing the synthesis of [18F]12, followed by attempts to optimize the conditions of the 
oxime ether formation. Both steps of the process were performed in a semi-automated syn-
thesis unit. Commercially available 1,3,4,6–O–Acetyl–2–O–trifluoro-methanesulfonyl–
beta–D–mannopyranose (10) was used as the precursor for the synthesis of [18F]12 in the 
first step.  
 
In the first step, triflate of compound 10 was substituted with [18F]F- by heating the mixture 
to 85 ℃ for 5 minutes. The removal of acetyl groups was performed with 1 M NaOH by 
slowly pushing the solution through the C18 cartridge. Due to the objective of using the 
[18F]12 for oxime formation with compound 3, the elution volume was desired to be kept 
as small as possible for a higher activity concentration. Most of [18F]12 eluted with the 
addition of NaOH, but an additional 2 mL of milli-Q water was added to ensure most of 
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the activity eluted out. This was later decreased to 1 mL as the second milliliter provided 
little to no additional activity into the product vial.  
 
With the first synthesis attempt of [18F]12, A total of 665.9 MBq [18F]12 was obtained at 
1.67 h. The initial activity was calculated with equation (1) 
 
𝐴଴ =
஺
ଶ
ష ೟೟భ/మ
=   ଺଺ହ.ଽ ெ஻௤
ଶష
భ.లలళ ೓
భ.ఴవఱ ೓
= 1225.09 𝑀𝐵𝑞 = 1225 𝑀𝐵𝑞. 
 
When taking into account the initial activity of [18F]F- immobilized in the QMA cartridge, 
the DCY of [18F]12 was calculated with equation (2) 
 
𝐷𝐶𝑌 = ஺బ (ி஽ோ)
஺బ (ிିଵ଼)
∙ 100% =  ଵଶଶହ.଴ଽ ெ஻௤
ଶ଴଺଼.ଵସ ெ஻௤
∙ 100% = 59.2363% = 60%. 
 
With the second attempt, [18F]12 was obtained with a radiochemical purity of 99% and a 
decay-corrected RCY of only 24% (463 MBq).  The decay corrections were calculated as 
previously by utilizing equations (1) and (2). The purity of [18F]12 was assessed by HPLC 
with both UV detection (figure 35) and radioactive detection (figure 36), and additionally 
by TLC (figure 37). The UV detection showed only a minor signal at 6.23 min, which was 
initially thought to belong to [18F]12. However, the radio-HPLC chromatogram showed a 
clear signal belonging to [18F]12 (radiochemical purity 99%) at 6.12 min. Thus, the UV 
signal likely belonged to some other compound, as a possible UV signal of [18F]12 should 
have come before the radioactive signal due to the physical location of both detectors in 
the HPLC system. The TLC chromatogram [18F]12 also demonstrated the relative purity of 
the compound (96.8%), with no indication of the partially acetylated forms of [18F]FDG 
present in the mixture. 
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Figure 35. HPLC chromatogram of a sample taken from reaction vial 2 after deprotection 
(second radiolabeling session). UV detection with wavelength 209 nm.  No clearly identi-
fiable UV signal was detected for [18F]12. The sample was analyzed with Alltima C18 
semi-preparative column (5 µm, 250 mm x 10 mm). The eluent system was acetoni-
trile/(0.5% TFA in milli-Q water) (1/1 v/v). The eluting gradient was increased from 5/95 
to 70/30 over 20 minutes, and lowered back to 5/95 after 10 minutes. The flow rate was 2 
mL/min 
 
 
Figure 36. Radio-HPLC chromatogram of reaction vial 2 after deprotection (second radio-
labeling session). Radiochemical purity of [18F]12 was 99%. The sample was analyzed 
with Alltima C18 semi-preparative column (5 µm, 250 mm x 10 mm). The eluent system 
was acetonitrile/(0.5% TFA in milli-Q water) (1/1 v/v). The eluting gradient was increased 
from 5/95 to 70/30 over 20 minutes, and lowered back to 5/95 after 10 minutes. The flow 
rate was 2 mL/min 
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Figure 37. Radio-TLC of [18F]12 (ACN/mQ 95/5 v/v). Radiochemical purity of [18F]12 
96.8% (first radiolabeling session) 
 
After the synthesis of [18F]12, conjugation with compound 3 was attempted. The initial 
attempt involved a neutralization step of [18F]12 where H3PO4 was utilized as the neutrali-
zation agent. The subsequent addition of compound 3 and aniline into the reaction mixture, 
however, led into the formation of an insoluble precipitate, which hindered the oxime for-
mation reaction, and as a result, no [18F]5 was detected in the subsequent analysis by 
HPLC. The culprit proved to be the combination of phosphoric acid and aniline. In the next 
radiolabeling attempt of [18F]5, the neutralization agent was replaced with 2 mL of 1 M 
HCl, which solved the issue.  
 
This time, the conjugation step was successful, as indicated by the HPLC chromatograms 
of both UV channel (figure 38) and radioactive channel (figure 39). A minor signal at 
10.66 min in the UV channel was detected, which corresponded well with the retention 
time of the cold compound [19F]5. However, it should be noted that the retention time of 
compound 3 with this method is similar (10.4 min) to the observed signal, and thus, the 
signal likely consisted of them both. Additionally, a large signal belonging to aniline was 
detected at 12.16 min. In the radioactive channel, three major signals were detected: 
[18F]12 at 6.12 min (30%), [18F]5 at 10.85 min (57%), and an impurity peak at 15.89 min 
(13%). This indicates that the radiolabeling reaction was not as specific as with [18F]4. One 
reason for this might be the lack of a DMT-Cl step, which was used in the radiosynthesis 
of [18F]4 to remove the precursor of the carbohydrate (figure 21), which likely competed 
with [18F]5 for oxime formation. 
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Figure 38. HPLC chromatogram of the reaction mixture containing [18F]5. UV detection 
with wavelength 209 nm. The sample was analyzed with Alltima C18 semi-preparative 
column (5 µm, 250 mm x 10 mm). The eluent system was acetonitrile/(0.5% TFA in milli-
Q water) (1/1 v/v). The eluting gradient was increased from 5/95 to 70/30 over 20 minutes, 
and lowered back to 5/95 after 10 minutes. The flow rate was 2 mL/min 
 
Figure 39. Radio-HPLC chromatogram of the reaction mixture containing [18F]5. The 
sample was taken from the reaction mixture after cooling down to room temperature, and 
after dilution with 0.25 M NaOAc buffer. Radiolabeling yield of 57% was obtained for 
[18F]5. The impurity peak (13%) was likely caused by to the presence of the carbohydrate 
precursor competing with [18F]12 for conjugation with precursor 3. The sample was ana-
lyzed with Alltima C18 semi-preparative column (5 µm, 250 mm x 10 mm). The eluent 
system was acetonitrile/(0.5% TFA in milli-Q water) (1/1 v/v). The eluting gradient was 
increased from 5/95 to 70/30 over 20 minutes, and lowered back to 5/95 after 10 minutes. 
The flow rate was 2 mL/min 
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Due to the presence of two radiochemical impurities and aniline as the chemical impurity, 
HPLC was chosen as the most appropriate method of purification. The viability of HPLC 
purification for [18F]5 was demonstrated in a small-scale experiment by injecting 100 µL 
of the reaction mixture into HPLC, and collecting the peak with a retention time of 10.7 
min. A total of 0.126 MBq of [18F]5 was obtained with this method, and the purified prod-
uct was used for the subsequent determination of LogD7.4 value for the compound.  
 
The stability and purity of [18F]5 was assessed two hours after the purification by HPLC 
with both UV detection (figure 40) and radioactive detection (figure 41). With UV detec-
tion, a minor signal was detected at 10.68 min, which corresponded well with the radioac-
tive signal of [18F]5 at 10.85 min. A minor signal was to be expected due to the small scale 
of the HPLC purification. Interestingly, the radio-HPLC chromatogram indicated the pres-
ence of a relatively large signal of [18F]12 at 6.12 min (11%) in addition to the signal of 
[18F]5 at 10.85 min (89%). The amount of 18F-labeled carbohydrate as an impurity was 
significantly higher with [18F]5 (11%) than with [18F]4 (2%). It is unlikely the presence of 
the free [18F]12 was the result of HPLC purification, as the retention times of [18F]5 (6.12 
min) and [18F]12 (10.85 min) differed greatly. One plausible reason for the free [18F]12 can 
be the relative instability of the oxime bond in an acidic environment as a function of time. 
This is supported by the notion that the HPLC-purified batch of [18F]5 was analyzed two 
hours after the initial purification in comparison to the analysis of [18F]4, which was per-
formed one hour after the purification. Interestingly, the UV channel showed no trace of 
aniline as a chemical impurity, likely due to the larger difference in their respective reten-
tion times. However, a small amount compound 3 (10.4 min) likely remained as an impuri-
ty. 
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Figure 40. HPLC chromatogram of the HPLC-purified batch of [18F]5. UV detection with 
wavelength 209 nm. The minor signal at 10.68 min likely belongs to [18F]5. The eluent 
system was acetonitrile/(0.5% TFA in milli-Q water) (1/1 v/v). The eluting gradient was 
increased from 5/95 to 70/30 over 20 minutes, and lowered back to 5/95 after 10 minutes. 
The flow rate was 2 mL/min 
 
 
Figure 41. Radio-HPLC chromatogram of HPLC purified [18F]5 (radiochemical purity of 
89%). The presence of [18F]12 (11%) was also evident two hours after the purification. The 
eluent system was acetonitrile/(0.5% TFA in milli-Q water) (1/1 v/v). The eluting gradient 
was increased from 5/95 to 70/30 over 20 minutes, and lowered back to 5/95 after 10 
minutes. The flow rate was 2 mL/min 
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3.3.5 Calculation of the distribution coefficient  
 
LogD7.4 values were determined for both [18F]4 and [18F]5 by a modified shake-flask 
method using gamma counting for the detection of the radiolabeled tracer in both 
phases.158 In the case of [18F]5, a small batch of the radiolabeled tracer was purified by 
HPLC to yield 0.126 MBq of the purified radiotracer, and approximately 10% (100 µl) of 
the batch was utilized for the subsequent lipophilicity determination. Similarly, 20 µL of 
the HPLC-purified batch of [18F]4 (3.09 MBq) was used to determine the lipophilicity of 
the FDR conjugate. The measurement data of [18F]4 and [18F]5 is shown in table (4) and 
(5), respectively. 
 
Table 4. Measurement data for the determination of logD7.4 for [18F]4. Measurement time 
60 seconds 
Sample 
Counts 
(CPM) 
Corrected counts 
(CPM) 
Weight 
(g) 
Counts/weight 
(CPM/g) 
1 (org. phase) 52 21.4 0.4032 53.0 
2 (buffer phase) 26216.8 26186.2 0.5139 50955.8 
3 (org. phase) 38.5 7.9 0.3976 19.8 
4 (buffer phase) 26132.3 26101.7 0.5112 51059.6 
5 (org. phase) 42.2 11.6 0.4064 28.5 
6 (buffer phase) 26043.9 26013.3 0.5224 49795.7 
7 (org. phase) 55.8 25.2 0.402 62.6 
8 (buffer phase) 25985.3 25954.7 0.5292 49045.1 
9 (background) 30.1    
10 (background) 31.2    
11 (background) 30.6    
Average (background) 30.6    
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Table 5. Measurement data for the determination of logD7.4 for [18F]5. Measurement time 
60 seconds 
Sample 
Counts 
(CPM) 
Corrected counts 
(CPM) 
Weight 
(g) 
Counts/weight 
(CPM/g) 
1 (org. phase) 37.2 -2.4 0.3962 -6.1 
2 (buffer phase) 7784.8 7745.2 0.5136 15080.2 
3 (org. phase) 46.9 7.3 0.3971 18.4 
4 (buffer phase) 7683 7643.4 0.5146 14853.1 
5 (org. phase) 44.5 4.9 0.3948 12.4 
6 (buffer phase) 7579 7539.4 0.5156 14622.6 
7 (org. phase) 55.6 16 0.3917 40.8 
8 (buffer phase) 7629.6 7590 0.5069 14973.4 
9 (background) 40.6    
10 (background) 38.6    
Average (background) 39.6    
 
An average value for the weight-corrected counts was calculated with equation (3). The 
examples shown herein are calculated for [18F]5 (1-octanol phase). The average number of 
counts in 1-octanol phase was calculated with equation (3). 
 
𝐴௢௖௧ =
15080.2181 + 14853.0898 + 14622.5756 + 14973.3675 
4
= 14882.31 
 
Standard deviation for the counts in 1-octanol phase was calculated with equation (4). 
 
𝑠௢௖௧ =
ඨ
(ଵହ଴଼଴.ଶଵ଼ଵିଵସ଼଼ଶ.ଷଵ)మା(ଵସ଼ହଷ.଴଼ଽ଼ିଵସ଼଼ଶ.ଷଵ)మ
ା(ଵସ଺ଶଶ.ହ଻ହ଺ିଵସ଼଼ଶ.ଷଵ)మା(ଵସଽ଻ଷ.ଷ଺଻ହିଵସ଼଼ଶ.ଷଵ)మ
ସିଵ
= 14.994. 
 
The distribution coefficient (logD7.4) was calculated with equation (5). 
 
𝐷଻.ସ =
23.88074
14882.31
= 0.001605 
 
The uncertainty of the D7.4 value was calculated with equation (6). 
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∆𝐷଻.ସ =  ඨ൬
14.994
14882.31
൰
ଶ
+ ൬−
196.4475 ∙ 23.8874
(14882.31)ଶ
൰
ଶ
 
= 0.001008 
 
By taking a log10 value of the distribution coefficient, the LogD7.4 value of [18F]5 was  
 
𝐿𝑜𝑔𝐷଻.ସ = log(0.001605) = −2.7946 = −2.79. 
 
The uncertainty of the logD7.4 value was calculated with equation (7). 
 
∆𝑙𝑜𝑔𝐷଻.ସ = ඨ൬
log(𝑒)
0.001605
∙ 0.001008൰
ଶ
 
= 0.272753 
 
Thus, the logD7.4 values for [18F]4 and [18F]5 were -3.1±0.2 and -2.8±0.3, respectively. 
The results along with their calculated uncertainties are shown in tables (6) and (7) for 
[18F]4 and [18F]5, respectively. 
 
Table 6. Results of the LogD7.4 calculation for [18F]4 
Quantity Value 
Octanol 41±20 CPM/g 
Buffer 50210±970 CPM/g 
D7.4 0.0008±0.0004 
LogD7.4 -3.1±0.2 
 
Table 7. Results of the LogD7.4 calculation for [18F]5 
Quantity Value 
Octanol 24±15 CPM/g 
Buffer 14900±200 CPM/g 
D7.4 0.002±0.001 
LogD7.4 -2.8±0.3 
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Interestingly, the LogD7.4 value of [18F]5 differs significantly from the results obtained by 
Bouvet et al. (2017) with a LogD7.4 value of -3.70 for the compound using the shake-flask 
method.120 The reason for the difference in obtained lipophilicity values is likely two-fold: 
the first reason being due to the presence of free [18F]12 in the HPLC purified fraction, 
which was observed two hours post-purification (figure 41). However, it should be noted 
that the determination of lipophilicity was performed 30 minutes after HPLC purification, 
so the true amount of free [18F]12 in the fraction was likely significantly less than the 11% 
shown in the figure, since the highly acidic media was diluted with 0.02 M phosphate buff-
er into a much larger volume. Nevertheless, even a minor amount of an impurity can sig-
nificantly affect the obtained logD7.4 value, especially since the log P value of [18F]12 (log 
P = -1.9) is significantly higher than the conjugated molecule.158 The second limitation of 
the experiment was due to the low activity of the octanol phase. Also, as shown in table 
(7), the standard deviation of the octanol phase was significant. Thus, the logD7.4 value for 
[18F]5 should be considered only as an indicative value of the compound’s hydrophilicity.  
 
The same issue wasn’t as prevalent with [18F]4 as it was with the FDG conjugate. Still, the 
relatively low activity in the octanol phase did create significant standard deviation, most 
likely altering the true logD7.4 value. Due to the novelty of the compound in question, no 
experimentally determined logD7.4 values exist in the current literature for comparison. 
Thus, to confirm the accuracy and reliability of the logD7.4 determination, both experi-
ments should be replicated at least twice to ensure the logD7.4 values of the compounds are 
as close to the true values as possible. Both activity and measurement time should also be 
increased to reduce the effect of inherent uncertainty of radioactive decay. Additionally, 
due to the acidic nature of the eluent mixture, and the possible instability of the oxime 
bond of the compounds in said media, the HPLC fractions containing [18F]4 and [18F]5 
should either be formulated into a more suitable form (for possible mice/patient injections), 
or at the very least, neutralized prior to the measurement to ensure the buffer capacity isn’t 
exceeded.  
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3.4 Conclusions  
 
The aim of this thesis was to develop two novel 18F-labeled PSMA inhibitors utilizing two 
well-established carbohydrate analogs as the prosthetic group: 5-[18F]fluoro-5-deoxyribose 
([18F]9) and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]12). This included the synthesis of the 
aminooxy-functionalized precursor 3, and the subsequent synthesis of cold reference com-
pounds [19F]4 and [19F]5, followed by their respective 18F-radiolabeled moieties [18F]4 and 
[18F]5.  
 
The radiosynthesis of [18F]9 was the first step in the radiolabeling sessions, where the aim 
was to synthesize the 18F-labeled carbohydrate, followed by immediate conjugation with 
the PSMA precursor 3 moiety. After several attempts at optimization, [18F]9 was success-
fully synthesized without HPLC purification, and with a radiochemical purity of 99%. 
[18F]9 was successfully conjugated with the aminooxy-functionalized precursor 3 to yield 
[18F]4 at room temperature using anilinium acetate buffer to catalyze the oxime formation. 
Experiments made during this thesis indicated that a reaction time of 15 min was enough 
for the completion of the reaction, with a radiolabeling yield up to 91% achievable with a 
peptide concentration of 1.5 mM. The reaction proved to be highly specific, with no ob-
servable by-product formation. 
 
The initial goal in the synthesis of the 18F-labeled 5-fluoro-5-deoxyribose ([18F]9) conju-
gated molecule ([18F]4) was to achieve the purification without HPLC by utilizing a Sep-
Pak C18 cartridge and aminolink™ resin in tandem. However, this proved to be unattaina-
ble due to the high hydrophilicity of the compound and thus, unacceptably low retention to 
the cartridge. Also, the C18 cartridge was unable to remove two other uncharacterized 
chemical impurities present in the reaction mixture. A suitable chemical and radiochemical 
purity was achieved eventually by subjecting [18F]4 to HPLC purification, yielding the 
product with a radiochemical purity of 98%. Minor deterioration of the oxime bond was 
observed one-hour post-purification, likely due to the presence of acidic TFA in the solu-
tion. The presence of a minor signal belonging to [18F]9 in the HPLC purified fraction of 
[18F]4 supports the notion that the oxime bond deteriorates slightly in acidic media. How-
ever, this is unlikely to prove problematic if formulation of the radiotracer is performed 
rapidly after purification. In any case, formulation of the radiotracer is necessary, as the 
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presence of TFA in the final formulation is unsuitable for any application involving injec-
tions into living organisms.  
 
The synthesis of the 2-[18F]fluoro-2-deoxy-D-glucose conjugate ([18F]5) was achieved with 
comparably harsh reaction conditions, including heating up to 85 ℃ for 30 minutes in the 
presence of aniline as the catalyst. The presence of a radioactive signal from an uncharac-
terized by-product with a longer retention time was also evident in the reaction mixture. 
The radiolabeling yield of [18F]5 was 57%, while the impurity was formed with a yield of 
13%. Additionally, the reaction was demonstrated with a relatively high peptide concentra-
tion of 9.8 mM. The purification by HPLC was also demonstrated with a smaller batch of 
the radiotracer. However, deterioration of the oxime bond was much more significant in 
this case, with the apparent radiochemical purity of [18F]5 being only 89% at two hours. As 
discussed previously, the deterioration can likely be diminished by immediate neutraliza-
tion and formulation of the product. It should also be noted that another group successfully 
achieved purification of [18F]5 without the use of TFA in the radiolabeling sessions.120 
However, the column and the HPLC gradient the group utilized differed somewhat (C12) 
from the one used in this study (C18).  
 
The lipophilicity of both synthesized radiotracers was also assessed by the shake-flask 
method. LogD7.4 values of -2.8±0.3 and -3.1±0.2 were obtained for [18F]5 and [18F]4, re-
spectively. This indicates both radiotracers were highly hydrophilic, likely possessing a 
rapid renal clearance, as could be expected when working with fluoroglycosylation. How-
ever, it should be noted that the experiments where the lipophilicity values were obtained 
had a few limitations. With [18F]5, the presence of free [18F]12 post-purification likely had 
a dramatic effect on the obtained value. Thus, the true logD7.4 value of [18F]5 was likely 
much smaller. Also, the shake-flask method for both radiotracers was performed with low 
activities, and thus, the obtained activity in the organic phase for both compounds was low, 
explaining the high standard deviation. To confirm the obtained values here, the lipophilic-
ity determination should be repeated, but with higher activities. Also, the lipophilicity de-
termination should be made from either a neutralized solution, or from a ready-for-
injection formulation to ensure the effect of the TFA in the pH of the phosphate buffer is 
negligible. It should also be noted the pH of the samples containing TFA weren’t checked 
prior to the logD7.4 determination. For this purpose, both [18F]4 and [18F]5 could be neutral-
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ized, and formulated into a solution with a minor concentration of ethanol (i.e. 2.5%) pre-
sent in the mixture to ensure the buffer capacity isn’t exceeded. 
 
There are several ways how the results obtained in this thesis could be improved with fur-
ther experiments. The activities of both [18F]9 and [18F]12 prior to oxime ether formation 
were low (8-10 MBq). If the compounds in question were to undergo in vivo trials, activi-
ties ranging in hundreds of MBqs would be more adequate. This can be achieved with at 
least two ways: (1) by scaling up the activities produced by the cyclotron at end of bom-
bardment, or (2) by optimizing the radiosynthesis procedure itself. For example, in the syn-
thesis of [18F]9, a large proportion of the activity was retained by the C18 cartridges prior 
to deprotection, indicating that the elution strength or volume of the 50% acetonitrile was 
insufficient. Additionally, a large amount of activity was detected in the washing solutions 
(milli-Q water). Also, only approximately ¼ of the produced [18F]9 was utilized for the 
oxime ether formation to retain a sufficient peptide concentration and a low end-volume. 
This could be improved by concentrating the [18F]9 into a smaller volume. 
 
The specificity and rapidness of the radiosynthesis of both [18F]4 and [18F]5 could also be 
investigated further. For example, it would be interesting to see how fast the reaction 
reaches completion. This could be achieved by taking samples from the reaction mixtures 
in specific timepoints, and by measuring the activity with radio-TLC. This was initially 
attempted with [18F]4, but the results couldn’t be replicated (80 % ACN eluent system). 
Thus, more optimization should be performed. This would be especially valuable for 
[18F]5, since the thirty-minute reaction time and subsequent cooling to room temperature is 
already lengthy. A Co-injection of the cold reference compounds into HPLC should also be 
performed to obtain better confidence about the identity of both [18F]4 and [18F]5. Also, a 
high peptide concentration was utilized during the experiments, so it would be interesting 
to see how low the peptide concentration could be decreased to without affecting the reac-
tion time or completion. Further experiments could also be made to determine the molar 
activity of both [18F]4 and [18F]5. It would also be interesting to see if a working cartridge 
purification method could be established for both compounds instead of the time-
consuming HPLC purification. For this purpose, other solid-phase extraction cartridges 
with a different retention mechanism, such as cationic or anionic exchangers, could be 
tested. 
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While the radiolabeling yield of [18F]4 was high at 91 %, the radiolabeling yield of [18F]5 
was anything but. The radiolabeling yield of [18F]5 could likely be improved by adding an 
additional step into the protocol with DMT-Cl, like with [18F]4, to see how it affects the 
radioactive signal of the detected impurity. However, it should be noted that this would 
increase the total synthesis time slightly. To compensate for the loss of activity, the best 
way to scale up the synthesis of [18F]5 would be as follows: (1) by increasing the activity at 
end of bombardment, and (2) by concentrating the end-volume of [18F]12. The concentra-
tion step is likely crucial if higher activities are desired, as only a volume of 200 µL of a 
total of 5 mL was utilized for the oxime ether formation to keep the peptide concentration 
as high as possible. By taking samples during the oxime ether formation at preset time 
points, the thirty-minute reaction time could likely be decreased as well. Due to the nature 
of radioactive decay, keeping the total synthesis time as low as possible is a necessity. Al-
so, the HPLC purification was only demonstrated with a small batch, and should be repeat-
ed with the entire batch in future experiments.  
 
In conclusion, two 18F-labeled PSMA inhibitors were successfully synthesized, with the 
formation of [18F]4 presenting more favorable oxime formation characteristics than [18F]5 
due to the more readily-available aldehydic form of the carbohydrate, and milder reaction 
conditions. At the start of the project, both compounds in question were novel, with no 
published in vitro or in vivo data available in the literature. However, several months into 
the project, another research group published data on the 2-[18F]fluoro-2-deoxy-D-glucose 
conjugated PSMA inhibitor. The results obtained by the group suggested the compound 
had poor PSMA inhibitory potency, with a IC50 value of 62 nM compared to the 13 nM of 
the current state-of-the-art 18F-labeled PSMA inhibitor, [18F]DCFPyL.120 This also casts in 
question the viability and potential of the 5-[18F]fluoro-5-deoxyribose conjugate as a viable 
PSMA inhibitor for PET imaging of prostate cancer due to the similarities in their struc-
ture. In the future, the viability of [18F]4 should be assessed in regard to its inhibitory po-
tency to better evaluate its potential as an alternative to [18F]DCFPyL. If the IC50 value of 
the 5-[18F]fluoro-5-deoxyribose conjugate proves to be comparable to the 2-[18F]fluoro-2-
deoxy-D-glucose conjugate, as can be expected based on their similar structure, it is likely 
not promising enough a candidate to warrant in vivo experiments. 
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Attachments 
List of attachments: 
 
Attachment 1. 1H-NMR of tri-tert-butyl 2,2-dimethyl-4,8,16-trioxo-3,6-dioxa-5,9,15,17-
tetraazaicosane-14,18,20-tricarboxylate (2) 
Attachment 2. 13C-NMR of tri-tert-butyl 2,2-dimethyl-4,8,16-trioxo-3,6-dioxa-5,9,15,17-
tetraazaicosane-14,18,20-tricarboxylate (2) 
Attachment 3. TOF-ESI-MS of tri-tert-butyl 2,2-dimethyl-4,8,16-trioxo-3,6-dioxa-
5,9,15,17-tetraazaicosane-14,18,20-tricarboxylate (2) 
Attachment 4. 1H NMR of (5-(2-(aminooxy)acetamido)-1-carboxypentyl)carbamoyl) 
glutamic acid (3) 
Attachment 5. TOF-ESI-MS of (5-(2-(aminooxy)acetamido)-1-carboxypentyl)carbamoyl) 
glutamic acid (3) 
Attachment 6. 1H-NMR spectrum of 21-fluoro-18,19,20-trihydroxy-5,13-dioxo-15-oxa-
4,6,12,16-tetraazahenicos-16-ene-1,3,7-tricarboxylic acid (4) 
Attachment 7. TOF-ESI-MS of 21-fluoro-18,19,20-trihydroxy-5,13-dioxo-15-oxa-
4,6,12,16-tetraazahenicos-16-ene-1,3,7-tricarboxylic acid (4) 
Attachment 8. 1H-NMR spectrum of 18-fluoro-19,20,21,22-tetrahydroxy-5,13-dioxo-15-
oxa-4,6,12,16-tetraazadocos-16-ene-1,3,7-tricarboxylic acid (5) 
Attachment 9. TOF-ESI-MS of 18-fluoro-19,20,21,22-tetrahydroxy-5,13-dioxo-15-oxa-
4,6,12,16-tetraazadocos-16-ene-1,3,7-tricarboxylic acid (5) 
Attachment 10. Printed chromatogram of the HPLC purification during radiolabeling of 
[18F]4 
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Attachment 1. 1H-NMR of tri-tert-butyl 2,2-dimethyl-4,8,16-trioxo-3,6-dioxa-5,9,15,17-
tetraazaicosane-14,18,20-tricarboxylate (2) 
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4.155
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1.991
0.961
2.394
46.74
PPM 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0
SpinWorks 3: 1H-NMR of compound 2
file: ...417-OA170328-OA170410-HPLC.fid\fid  block# 1  expt: "s2pul"
transmitter freq.: 299.951549 MHz
time domain size: 25000 points
width: 5000.00 Hz = 16.6694 ppm = 0.200000 Hz/pt
number of scans: 16
freq. of 0 ppm: 299.950105 MHz
processed size: 32768 complex points
LB: 0.048    GF: 0.0000
Hz/cm: 105.556    ppm/cm: 0.35191
1.4350
1.4532
1.4629
1.4883
8.1023
7.9068
5.3359
4.3388
3.3320
2.3202
2.0807
1.8119
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Attachment 2. 13C-NMR of tri-tert-butyl 2,2-dimethyl-4,8,16-trioxo-3,6-dioxa-5,9,15,17-
tetraazaicosane-14,18,20-tricarboxylate (2) 
 
 
PPM 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
SpinWorks 3: 13C-NMR of compound 2
file: ...C-OA170328-OA170410-CARBON.fid\fid  block# 1  expt: "s2pul"
transmitter freq.: 75.430045 MHz
time domain size: 40000 points
width: 20000.00 Hz = 265.1463 ppm = 0.500000 Hz/pt
number of scans: 200
freq. of 0 ppm: 75.422502 MHz
processed size: 65536 complex points
LB: 3.500    GF: 0.0000
Hz/cm: 541.778    ppm/cm: 7.18252
172.8655
172.6131
169.2962
157.8673
157.1823
83.0712
82.2059
81.6651
80.5835
77.5551
77.2306
76.7492
76.0048
53.5172
53.1116
38.3900
32.2610
31.7853
28.8720
28.4754
28.1724
22.1660
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Attachment 3. TOF-ESI-MS of tri-tert-butyl 2,2-dimethyl-4,8,16-trioxo-3,6-dioxa-
5,9,15,17-tetraazaicosane-14,18,20-tricarboxylate (2) 
 
Positive mode. Compound 2 identified at 661.3756 [M+H+], sodium adduct at 683.3575 
[M+Na+] and potassium adduct at 699.3315 [M+K+] 
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Attachment 4. 1H NMR of (5-(2-(aminooxy)acetamido)-1-carboxypentyl)carbamoyl) 
glutamic acid (3) 
 
 
 
  
0.998
0.984
0.495
0.515
0.465
0.462
0.915
0.903
0.956
0.910
PPM 4.8 4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.0 1.8 1.6 1.4 1.2 1.0
SpinWorks 3: 1H-NMR of compound 3. HPLC-purified
file: ...OA170817-d2o-hplc-purified.fid\fid  block# 1  expt: "s2pul"
transmitter freq.: 299.952320 MHz
time domain size: 25000 points
width: 5000.00 Hz = 16.6693 ppm = 0.200000 Hz/pt
number of scans: 64
freq. of 0 ppm: 299.950836 MHz
processed size: 32768 complex points
LB: 0.048    GF: 0.0000
Hz/cm: 49.778    ppm/cm: 0.16595
4.6208
4.2774
3.3162
2.5648
2.2237
2.0324
1.8941
1.7766
1.6175
1.4723
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Attachment 5. TOF-ESI-MS of (5-(2-(aminooxy)acetamido)-1-carboxypentyl)carbamoyl) 
glutamic acid (3) 
 
Positive mode. Compound 3 identified at 393.1640 [M+H+], sodium adduct at 415.1419 
[M+Na+] and potassium adduct at 431.1188 [M+K] 
 
 
  
Negative mode. Compound 3 identified at 391.1447 [M-H+], sodium adduct at 413.1012 
[M-Na+-2H+] and potassium adduct at 429.1012 [M-K+-H+] 
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Attachment 6. 1H-NMR spectrum of 21-fluoro-18,19,20-trihydroxy-5,13-dioxo-15-oxa-
4,6,12,16-tetraazahenicos-16-ene-1,3,7-tricarboxylic acid (4) 
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SpinWorks 3: 1H-NMR of compound 4. HPLC-purified
file: ...828-d2o-frau-hplc-purified.fid\fid  block# 1  expt: "s2pul"
transmitter freq.: 299.952320 MHz
time domain size: 25000 points
width: 5000.00 Hz = 16.6693 ppm = 0.200000 Hz/pt
number of scans: 64
freq. of 0 ppm: 299.950839 MHz
processed size: 32768 complex points
LB: 0.048    GF: 0.0000
Hz/cm: 82.667    ppm/cm: 0.27560
1.4499
1.5915
1.7676
1.8747
2.0317
2.2231
2.5637
3.3025
3.4441
3.9341
4.2250
4.3054
4.6154
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7.7466
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Attachment 7. TOF-ESI-MS of 21-fluoro-18,19,20-trihydroxy-5,13-dioxo-15-oxa-
4,6,12,16-tetraazahenicos-16-ene-1,3,7-tricarboxylic acid (4) 
 
Positive mode. Compound 4 identified at 527.1982 [M+H+], sodium adduct at 549.1782 
[M+Na+] and potassium adduct at 565.1456 [M+K+].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
112 
 
Attachment 8. 1H-NMR spectrum of 18-fluoro-19,20,21,22-tetrahydroxy-5,13-dioxo-15-
oxa-4,6,12,16-tetraazadocos-16-ene-1,3,7-tricarboxylic acid (5) 
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SpinWorks 3: 1H-NMR of compound 5. HPLC-purified. Dissolved in D2O
file: ...aoa-fdg-nt64-hplc-purified.fid\fid  block# 1  expt: "s2pul"
transmitter freq.: 299.952320 MHz
time domain size: 25000 points
width: 5000.00 Hz = 16.6693 ppm = 0.200000 Hz/pt
number of scans: 64
freq. of 0 ppm: 299.950839 MHz
processed size: 32768 complex points
LB: 0.048    GF: 0.0000
Hz/cm: 84.111    ppm/cm: 0.28041
1.4549
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1.7420
1.8532
2.0106
2.1680
2.5292
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3.8257
4.2332
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Attachment 9. TOF-ESI-MS of 18-fluoro-19,20,21,22-tetrahydroxy-5,13-dioxo-15-oxa-
4,6,12,16-tetraazadocos-16-ene-1,3,7-tricarboxylic acid (5) 
 
Negative mode. Compound 5 identified at 555.1955 [M-H+] 
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Attachment 10. Chromatogram of the HPLC purification during radiolabeling of [18F]4 
 
 
